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ABSTRACT 
Characterization of terrelysin, a potential biomarker for Aspergillus terreus 
Ajay Padmaj Nayak 
 
Exposure to fungi can lead to diverse conditions from allergy to colonization to invasive 
and disseminated infection, depending on the status of the host immune system. Recent data 
suggests that fungal infections and especially Aspergillus species has been on the rise. Though 
mostly affecting immunocompromised individuals, more recent reports have identified infections 
in immunocompetent populations as well. Aspergillus terreus is of particular interest, since it 
causes rapid disseminating infections with high mortality rates, owing to its natural resistance to 
antifungal drugs and production of vegetative aleurioconidia during infection. These attributes 
coupled with poor current diagnostics and increasing costs involved with controlling the 
infection, have generated considerable interest in developing novel strategies for diagnosis of A. 
terreus infections. Fungal hemolysins have been proposed as biomarkers of exposure because of 
an association between exposures to the black mold Stachybotrys chartarum and an outbreak of 
idiopathic pulmonary hemorrhage. Using polyclonal antibodies, the hemolytic antigen was 
detected at concentrations of 371 ng/ml in patient sera. Our initial experiments were designed to 
develop monoclonal antibodies (mAbs) towards a stachylysin hemolytic preparation. IgM mAbs 
were developed with limited cross-reactivity within Stachybotrys species. ELISA and FHIA 
analysis showed that most stachylysin was present in hyphae. Using proteomic analysis, we 
could not confirm the identity of stachylysin because the genome of S. chartarum has not been 
sequenced. To better characterize hemolysins as biomarkers, the clinically relevant fungus (A. 
terreus) with a sequenced genome was chosen for analysis. Initial attempts at the 
characterization of a hemolytic fraction from A. terreus resulted in development of multiple A. 
terreus-specific IgG1 mAbs to proteolytic enzymes including, leucine aminopeptidase and 
dipeptidyl peptidase V. We were unable to identify the hemolysin of interest using this mAb 
approach. Alternatively, expression of recombinant terrelysin (rTerrelysin) using the pASK-
IBA6 vector in Escherichia coli yielded a protein with secondary structure similar to other 
Aegerolysin family proteins. Highly specific mAbs (10G4, 15B5 and 13G10) to the recombinant 
protein consistently recognized native terrelysin in different strains of A. terreus. Expression 
kinetics suggested that terrelysin is produced in high concentrations immediately after 
germination but levels decrease with increasing fungal biomass, and not present at the later time 
points when the previous hemolytic preparations were made. These data suggest interpretation of 
previous studies on detection of ‘hemolysins’ in exposed individuals and experimental animals 
are likely an error. The mAbs developed in this study for terrelysin, leucine aminopeptidase, and 
dipeptidyl peptidase V have potential for development of rapid and specific diagnostic assays. 
Tools developed in this study could be used for analysis in various animal models to determine 
combinatorial assays using mAbs developed to different proteins of A. terreus. 
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1.1 INTRODUCTION 
Fungi are one of the most ubiquitous groups of eukaryotic organisms in nature. Kingdom 
Mycota includes an estimated 1.5 million species of eukaryotic organisms including yeasts, 
molds and mushrooms. They characteristically lack chlorophyll and are saprophytes i.e. they 
depend on external sources of organic material for nutrition. In nature, they play an important 
role in recycling elements in soil. They are used in industry as a source of enzymes and 
important secondary metabolites that have tremendous economic and therapeutic value. 
Exposure of human population is ubiquitous and a growing number of individuals with impaired 
immune systems are susceptible to infections from these microbes, thus making them clinically 
relevant. 
Within the Kingdom Mycota, fungi are divided based on distinguishing characteristics, 
with specific emphasis on the different reproductive stages. Kingdom Mycota is further divided 
into seven Phyla (1); Phylum Glomeromycota consists of fungi that have an important role in 
the ecosystem and form mutualistic symbiotic relationship with plants; fungi belonging to Phyla 
Chytridiomycota, Blastocladiomycota and Neocallimastigomycota are characterized by 
flagella and are present mostly in aquatic environment; Phylum Microsporidia consists of spore-
forming unicellular obligate parasites; and Phyla Basidiomycota and Ascomycota represent the 
largest number of fungal species known and have been grouped together under the Sub Kingdom 
Dikarya. 
Ascomycota, the largest and most diverse Phyla consists of approximately 64,000 species 
(2). Members of Ascomycota are present in most natural and industrial environments. They have 
also been surprisingly isolated from extreme environments (3-5). Ascomycetes include fungi that 
are important in industry for their enzymes and secondary metabolites that have nutritional and 
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therapeutic value. Ascomycetes also include of large number of species that can cause 
opportunistic infections in humans, animals and plants particularly Aspergillus and Penicillium. 
 
1.2 MORPHOLOGICAL CHARACTERISTICS  
Stachybotrys and Aspergillus spp, two filamentous fungal species that are the focus of 
this work, are molds that exist in the form of non-motile conidia or hyphae. Their perseverance is 
highly dependent on the availability of moisture and nutritive material. Typically, filamentous 
fungi exhibit the following morphological structures (6); 
1.2.1 Conidium- Conidium (pl. conidia) also referred to, as a spore, mitospore or 
conidiospore is the dormant form of the fungus that acts as a secure ‘house’ for survival of the 
fungus in presence of adverse environmental conditions. The conidium has a highly structured 
external cell wall composed of α or β (1-3) glucan-proteins and chitin fibrils. In addition, 
pigments such as melanin are also associated with the conidial cell wall. Small hydrophobic 
proteins, called as hydrophobins coat the outer surface of conidia and this coating protects the 
conidia from dehydration and allows for attachment of conidia to various surfaces (6, 7). 
Ergosterol is present in the membrane and functions similarly to cholesterol in mammalian cells.  
On access to nutrients and water, various signaling molecules initiate the process of 
germination, resulting in swelling of the conidia, differential expression of proteins, and changes 
in surface properties (8-10). The first evidence of hyphal growth is observed in the form of a 
developing germ tube. An important feature of germinated conidia is its increased adhesive 
property and a polarized cellular growth. At this stage, the outer coat that existed on the conidia 
is completely shed and is identified as a germling. 
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1.2.2 Hypha- Hypha (Pl. hyphae) extends from germinating conidia and continues expansive 
cellular growth. These structures are identified as the vegetative form of the fungus, usually 
identified during infections. The hyphal cell wall is thinner than the conidial cell wall and this 
allows for an easy flow of nutrients into the cell. Hyphae are multicellular and may (Aspergillus 
species) or may not (Mucor species) be divided into compartments by septa. Septa are usually 
incomplete and do not lead to permanent compartmentalization i.e. they allow the transport of 
ribosomes, mitochondria, nuclei and other organelles between compartments.  
 
1.2.3 Mycelium- Mycelium (Pl. mycelia) is an aggregate of an extensive network of 
intertwining hyphae. Mycelia play a critical role in the environment in cycling of elements by 
degrading organic material. The mycelial stage also allows for aggressive utilization of organic 
materials available in the environment. 
 
1.2.4 Foot cell, conidiophore and vesicle- As nutrient and water availability decreases, the 
cell resorts to producing conidia for promoting survival. Along the hypha, a stalk-like structure 
emerges to form a conidiophore. The basal cell from which the conidiophore arises is identified 
as the foot cell. The conidiophore produces conidia on a funnel-like structure called a vesicle. 






1.3 FUNGAL DIAGNOSTICS 
Diagnosis of fungal infections and specifically detection of filamentous fungal species 
has been challenging (11-14). Treatment of symptoms including prolonged fever and a condition 
of neutropenia with unresponsiveness to antibacterial therapy is usually followed by antifungal 
agents. This lag period can result in severe recalcitrant fungal infections, making it imperative to 
diagnose fungal infections early. The following methods have been used either singly or in 
combination to diagnose the fungal infection etiology (14); 
 
1.3.1 Culture methods- Isolation of fungi has been possible from cutaneous and superficial 
infections (15), however fungal recovery from invasive infections is inconsistent and unreliable 
(16-23). Fungemia may not occur even though mycological evidence is clear in infected tissues 
(23-25). Detection of aleurioconidia (conidia produced by vegetative hyphae) can be definitive 
for identification of A. terreus (26) however, other fungi such as Fusarium, Paecilomyces, 
Scedosporium and Acremonium species may release morphologically similar vegetative conidia 
in tissues and blood during infection, thus making differentiation complicated (23). The overall 
low sensitivity and inconsistency of isolation and differentiation make macroscopic and 
microscopic determination difficult at species level.  
 
1.3.2 Molecular methods- DNA based methods are rapid and definitive and the presence of 
fungal DNA from sterile sites such as blood or other affected tissues (except lung) could possibly 
hold diagnostic value. A few studies have reported success from using PCR based techniques at 
qualitative as well as quantitative levels (27, 28). PCR methods have been developed using 
specific genes such as ribotoxin (29), tRNA (30), cytochrome b (31) and 18S rRNA (32, 33) as 
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primer targets. Notwithstanding the popularity and demand for PCR based diagnostics, currently 
there is no FDA-approved fungal diagnostic PCR testing systems available. Certain experimental 
and methodological limitations hinder the use of PCR methods. Isolation of fungal DNA from 
clinical samples is unreliable and success rate varies between various methods (34). Detailed 
information on advantages and disadvantages of using PCR based methods has been reviewed 
extensively elsewhere (14, 35). 
 
1.3.3 Radiological techniques- Radiological scanning techniques used for diagnosis of 
invasive aspergillosis may be suggestive of an active infection but are not species specific for 
developing targeted therapeutics (36, 37). Chest radiograph can help in identification of 
aggregated fungal mass in the lungs (38). Computed tomography exhibits higher sensitivity 
compared to other radiological techniques especially during early stages of infection (39). 
Collectively, these observations in collaboration with clinical manifestations of aspergillosis 
have been used successfully in improving the outcomes of invasive aspergillosis, but limitations 
hinder the use of these techniques especially in pediatric populations (40).  
 
1.3.4 Histology- The lung is not considered a sterile site for etiological determination during 
fungal infections, since many different fungi may also be isolated. This makes clinical samples 
such as bronchial lavage and sputum less than ideal for the diagnostic detection of fungal 
material. However, histological confirmation of invasive vegetative hyphae or positive culture 
from biopsies of sterile sites such as pleural fluid may hold diagnostic value (41). Commonly 
used staining procedures stain for carbohydrate moieties that are shared by most fungi aid in 
ascertaining fungal growth but are not species specific (14).  
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1.3.5 Serology- One of the biggest advantages of developing serological diagnostics for 
invasive aspergillosis is that it obviates the need for invasive procedures (41). Historically 
however, serological immunodiagnosis has been difficult due to unreliable antibody responses 
and insensitive results (42-45). Humoral antibody responses to Aspergillus species during 
invasive infection can be weak due to the immunocompromised nature of these patients. 
Measurement of serum galactomannan (46) and β-D-glucans, which constitute the fungal cell 
wall have been widely used with some success in diagnosis of invasive fungal disease (35). 
Galactomannan is a polysaccharide with a mannose backbone and galactose side chains, while β-
D-glucans are polysaccharides with D-glucose monomers linked by β-glycosidic bonds. While 
these assays are currently used for diagnosis of invasive fungal diseases, they lack sensitivity and 
detection is not species specific, which results in inconsistent determinations (14, 47, 48).  
 
1.3.6 Biomarkers for immunodiagnostics- Detection of circulating antigens expressed by 
vegetative hyphae using species-specific monoclonal antibodies holds potential for developing 
ideal immunodiagnostics (49). Some have reported the presence of circulating protein antigens in 
infected patients (50-52). To have diagnostic value, prospective biomarkers should be expressed 
in the vegetative hyphae and preferably secreted by the growing hyphae. Detection of the 
biomarker should be rapid and species specific. The development of monoclonal antibodies for 
detection of the biomarker is essential to maintain species specificity in detection. This also 





1.4 FUNGAL HEMOLYSINS 
Fungal hemolysins have been suggested as specific biomarkers for fungal exposure (53-
55), as they have been detected in sera and tissues of patients and experimental animals (53, 56). 
Hemolysins are pore-forming toxins that can lyse membranes of red blood cells. Though they are 
typically called hemolysins because of their ability to lyse red blood cells, many are capable of 
lysing other eukaryotic cells as well. Hemolysins and their role as virulence factors have been 
extensively studied in bacteria (57, 58); however less is understood about fungal hemolysins and 
their role in pathogenesis. 
Hemolytic activity was first identified in fungi by Henrici in 1939 in mycelial extracts of 
A. fumigatus and was later reported in other fungal species by Salvin in 1951 (59, 60). 
Subsequently, hemolytic activity has been reported for many fungal species and the hemolysins 
have been identified and are summarized in Table 1.1. The first fungal hemolysin to be purified 
was from A. fumigatus; called asp-hemolysin. Similar hemolysins have been identified in other 
fungi and are currently identified as a family of proteins called Aegerolysins. Increasing interest 
in these proteins has led to improved understanding of the mechanisms underlying their 
hemolytic activity, role as virulence factors, binding to lipoproteins, and diagnostic potential as 











Aspergillus clavatus YES (62) 
Aspergillus flavus YES (59, 63, 64) 
Aspergillus fumigatus YES (56, 59, 62, 65-75) 
Aspergillus nidulans YES (76, 77) 
Aspergillus niger YES (78-81) 
Aspergillus oryzae YES (82, 83) 
Aspergillus terreus YES (84) 
Alternaria tenuis NO (85) 
Blastomyces dermatidis YES (60, 86-88) 
Candida albicans NO (60, 89, 90) 
Candida glabrata NO (91) 
Coccidioides posadasii YES (92) 
Cordyceps militaris YES (93) 
Cryptococcus neoformans NO (60) 
Fusarium oxysporum YES (94) 
Histoplasma capsulatum YES (60, 92, 95-97) 
Metarhizium acridum YES (98) 
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Metarhizium anisopliae YES (98) 
Nectria haematococca YES (99) 
Neurospora crassa YES (100) 
Neurospora tetrasperma YES (101) 
Paracoccidioides brasiliensis YES (102-104) 
Penicillium chrysogenum YES (105, 106) 
Sordaria macrospora YES (107) 
Stachybotrys chartarum NO (53, 108-112) 
Trichophyton species NO (113) 
BASIDIOMYCETES  
Moniliophthora perniciosa YES (114, 115) 
Agrocybe aegerita YES (116, 117) 
Pleurotus eryngii YES (118, 119) 
Pleurotus ostreatus YES (117, 120-132) 
Pleurotus nebrodensis NO (133) 
Amanita phalloides NO (134-142) 
Amanita rubescens NO (139, 143-146) 
Hypholoma fasciculare NO (139) 
Laetiporus sulphureus NO (147-149) 
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Rhodophyllus rhodopolius NO (150) 
Flammulina velutipes NO (151-156) 
Volvariella volvacea NO (157) 
Termitomyces clypeatus NO (158) 
Schizophyllum commune NO (159) 
Wallemia sebi NO (160) 
ZYGOMYCETES  
Rhizopus nigricans NO (161, 162) 
Rhizopus arrhizus NO (161) 
 
Table 1.1: Hemolytic activity of different fungal species. *This strain is now identified as 
Stachybotrys chlorohalonata (163). 
 
1.5 AEGEROLYSINS 
1.5.1 General characteristics- Current information on the Aegerolysin family proteins (Pfam: 
PF06355; InterPro: IPR 009413) is largely based on studies of asp-hemolysin (A. fumigatus) and 
ostreolysin (P. ostreatus) (61). The Aegerolysin protein domain is currently identified in 114 
sequences spread across fungi, bacteria, plants and a virus (Appendix A2). The Pfam protein 
database provides information on species distribution of the aegerolysins (164). Aegerolysin 
proteins are typically 15-20 kDa in size and are rich in negatively charged residues (61, 117, 
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165). The isoelectric point of aegerolysins is acidic and has been experimentally determined for 
ostreolysin (pI 5.0), and aegerolysin (pI 4.85) (117).  
 
1.5.2 Hemolytic and cytolytic activity- Fungal hemolytic activity was initially reported from 
crude or partially purified mycelial extracts (63, 166-168). Improvements in biochemical 
techniques contributed to purification of asp-hemolysin from A. fumigatus (169). Asp-hemolysin 
was identified to form distinctive pores on the surface of cell membranes to induce lysis by the 
colloid-osmotic mechanism (170). Detection of asp-hemolysin in vivo during infection of A. 
fumigatus has led to suggestions that the protein may be important for pathogenesis (49, 171). 
The hemolytic activity is stable in a wide range of pH (65, 119, 123, 169, 170, 172). Other 
studies have characterized the ability of these proteins in lysing red blood cells and other 
eukaryotic cells from different animal species (APPENDIX A3). 
Pore forming toxins bind to diverse receptors on the surface of target cells (173-175). 
Membrane lipid receptors for aegerolysins were identified by partitioning of ostreolysin to 
detergent resistant membranes (DRMs) in natural and artificial systems (122). Ostreolysin did 
not bind pure cholesterol (117, 121). Binding occurred when cholesterol was combined with 
sphingomyelin (122, 126). In further studies, removal of cholesterol from membranes of CHO-
K1 cells by methyl β-cyclodextrin inhibited binding of ostreolysin (176). 
 
1.5.3 Studies in experimental animals- Several studies have characterized the effects of 
fungal hemolysins in vivo (59, 61, 63, 125). The intravenous (i.v.) LD50 value for asp-hemolysin 
in mice is reported to be 750 µg/kg (169) and that for ostreolysin was higher at 1170 µg/kg for 
mice (125). For ostreolysin, concentrations higher than LD50 value resulted in death of 
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experimental animals within 20 mins. In an interesting study, injecting asp-hemolysin i.v. 
simultaneously with non-lethal dose of A. fumigatus conidia increased the mortality rates in 
experimental mice (56). Injecting asp-hemolysin also aided in improved survival of A. fumigatus 
conidia within the animals. More interestingly, mice immunized i.p. with anti-asp-hemolysin 
antibodies before A. fumigatus conidial challenge promoted survival of the animals.  
Asp-hemolysin has also been detected in infected tissues of mice challenged with A. 
fumigatus conidia (177). Intravenous administration of experimental animals with asp-hemolysin 
showed that it can bind to arterial walls in the kidneys, heart, liver and the brain. Binding 
resulted in thickening of epithelial cells in the kidney, degeneration and necrosis of the cardiac 
muscles in heart, necrosis of liver cells with pyknosis and focal lesion and hemorrhage in brain. 
Asp-hemolysin also induced contraction of guinea pig ileum. 
 Studies using ostreolysin have also yielded similar results in terms of toxicity. 
Intravenous administration of ostreolysin resulted in hyperkalaemia, which resulted from lysis of 
host cells (125). This observation was further supported in another study where increasing doses 
of ostreolysin lead to development of tension in isolated rat aortic rings and diminished the 
relaxation of endothelium (129). This in combination with cytotoxicity towards human umbilical 
vein endothelial cells suggests a possible role in cardiotoxicity for these proteins.  
 
1.5.4 Role of aegerolysin proteins in biology of the organisms- Initial studies identified that 
expression of hemolysins is specific for the vegetative hyphae and suggest a role during the early 
stages of immature fruiting bodies (116). Studies with ostreolysin and aegerolysin highlighted 
that the expression of these proteins varies with the morphological changes occurring in 
developing mushrooms (117). Ostreolysin is expressed by the growing hyphae and it may play a 
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role in aggregation and compaction of hyphae to form primordia (117, 124). Addition of 
ostreolysin externally enhanced hyphal aggregation and formation of fruiting bodies (127). A 
clearer understanding of the role of these proteins in filamentous fungi is needed. 
 
1.6 FUNGAL HEMOLYSINS AS BIOMARKERS 
Interest in use of hemolysins as specific biomarkers for fungal exposure developed first 
in cases of infant idiopathic pulmonary hemorrhage (IPH) reported from water damaged homes 
in Cleveland, OH which resulted in mortality (178, 179). Exposure to water-damaged homes 
resulted in 8 infants with IPH and 1 mortality and further investigation suggested the black mold, 
Stachybotrys chartarum was the etiological agent responsible for IPH (180-182). 
S. chartarum is a dematiaceaous fungus that has been associated with a number of human 
and veterinary health problems (108). S. chartarum is particularly adept at growing on water 
infiltrated cellulose-based building materials. The morphological features of S. chartarum are 
characterized by septate hyphae and conidiophores that bear clusters of phialides from which 
chains of dematiaceaous conidia emerge. Identification of Stachybotrys conidia in tape lift or air 
samples in indoor environments is considered a biomarker of indoor fungal contamination by 
various federal, state, and academic institutions. Stachybotrys conidia and hyphae contain 
mycotoxins, allergens, proteases, and other immunostimulatory molecules (183, 184). Personal 
exposure to S. chartarum is also considered an etiological agent for respiratory disease (180-
182).  
Initial investigation of the water-damaged homes in Cleveland, Ohio led to identification 
of mold contamination and isolation of multiple strains of S. chartarum (108, 185). Toxicity 
studied in strains isolated from water damaged homes and control homes suggested additional 
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factors might be responsible for the pathogenicity. S. chartarum strains isolated from water 
damaged homes exhibited hemolytic activity in vitro when grown on wet wallboards at 37°C 
(108).  
Hemolytic activity has often been associated with pathogenesis of various 
microorganisms (58, 186-190). Three strains of S. chartarum isolated from the homes in 
Cleveland where infants became sick (Cleveland strains) and from the lung of an infant patient in 
Houston (Houston strain) suffering from IPH showed high toxicity and hemolytic activity, 
suggesting a possible correlation between the hemolysin and IPH (108, 109, 111, 185, 191). 
Cleveland and Houston strains of S. chartarum exhibited higher levels of hemolytic activity 
compared to control strains (109).  In a later study it was reported that when all S. chartarum 
strains were grown in medium containing blood, culture supernatant (CSN) concentrate from all 
the strains exhibited hemolytic activity (111). These observations have been reported in a prior 
study (109). 
Further studies led to partial purification of the hemolytic protein of S. chartarum, 
stachylysin and its initial biochemical characterization (110). The authors emphasized that 
purification of the hemolytic principle from the fungi and generation of antibodies could help 
develop diagnostic assays to determine fungal exposure. Detection of the hemolysin would in 
principle act as a surrogate biomarker for S. chartarum exposure. Initial characterization of 
stachylysin suggested it could be an aegerolysin including; 1) Using MALDI-TOF, stachylysin 
was identified as an ~12 kDa protein, which is the typical size of aegerolysin proteins. 2) 
Stachylysin contains large number of negatively charged amino acids also typically associated 
with aegerolysin proteins. 3) Kinetics of hemolysis was similar to that of ostreolysin, presenting 
an initial lag prior to hemolysis, suggesting aggregation of monomers on the surface of target 
 16
cells. 4) The hemolytic activity of stachylysin was compromised on heat treatment at 60°C for 30 
min. Aegerolysin proteins are heat-labile and lose their hemolytic activity at temperatures above 
65°C. 
Previously, the role of hemolysins in causing hemorrhagic lesions in experimental 
animals exposed to asp-hemolysin from A. fumigatus was established (169). The possible 
involvement of stachylysin in IPH was suggested based on studies performed in an earthworm 
(Lumbricus terrestis) model (111). Stachylysin injected into L. terrestis resulted in release of 
eythrocruorin hemoglobin and lethality. Furthermore, lung tissues from mice and rat exposed to 
S. chartarum conidia via intra-tracheal instillation developed granuloma and stachylysin was 
immuno-stained surrounding the conidia in the mouse lung suggesting its diffusion and possible 
role in damage to the tissue (112).  
In a critical study in identifying this hemolysin as a biomarker for detection of exposure 
to S. chartarum, stachylysin was detected in sera of rats exposed to S. chartarum conidia using 
anti-stachylysin polyclonal antibodies raised in rabbits (53). In the same study, the data 
suggested that stachylysin could be detected in sera from human subjects exposed to S. 
chartarum in a water-damaged environment. Since, the levels recorded were extremely high (371 




Fungal hemolysins have been characterized for their role in fungal development and have 
been suggested as putative biomarkers for pathogenesis. Studies have identified that hemolysins 
are expressed in high concentrations in mycelium, which is the infective stage of fungi. There is 
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limited evidence that these hemolysins might also be present in fungal conidia. Some studies 
have also used polyclonal antibodies to detect fungal hemolysins in sera of patients. Collectively, 
these observations substantiate the utility of hemolysins as putative biomarkers for fungal 
exposure. 
We hypothesize that hemolysins are secreted during initial stages of germination and that 
high concentrations could be present in mycelium. Since mycelium is the invasive stage of 
infection, high concentration of hemolysins could be present during active infection. Hemolysins 
may be released into the surrounding tissues including blood and thus may be available for 
identification as a biomarker. In the following research we have characterized the production of 
hemolysins from Stachybotrys and Aspergillus terreus to determine their suitability as potential 
biomarkers. A previously uncharacterized hemolysin (terrelysin) from A. terreus was identified 
and further characterized by producing a recombinant protein expressed in Escherichia coli. 
Recombinant terrelysin was used to develop monoclonal antibodies (mAbs) as research tools for 
characterization of terrelysin production and expression in the fungi. Finally, we explore the 
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2.1 INTRODUCTION 
Filamentous fungi belonging to Stachybotrys species are occasionally isolated as 
contaminants of indoor and outdoor air. Stachybotrys are widely present and currently, 55 
species of Stachybotrys including Memnoniella are known (1). Stachybotrys species produce 
trichothecene mycotoxins called as satratoxins, which bind to eukaryotic ribosomes and act as 
inhibitors of protein synthesis (2, 3). Stachybotrys species also produce proteinases that 
contribute to lung inflammation and injury through degradation of host collagen and can induce 
activation of a pro-inflammatory response (4). 
S. chartarum exhibits hemolytic activity, which has been attributed to its hemolysin, 
stachylysin (5-8). Moreover, the detection of stachylysin in sera of experimental animals and 
patients with known exposure to S. chartarum in indoor environment provided an impetus for 
development of specific immunodiagnostic methodologies (9). However, polyclonal antibodies 
(pAbs) used in this study can lack specificity and are cross reactive as reported in previous 
studies in our laboratory (10-13). pAbs are also prone to batch-to-batch variability, which may 
influence the development of standardized assays. In order to overcome these limitations, we 
aimed to develop monoclonal antibodies (mAb) to stachylysin that were species-specific. 
Compared to pAb-based methodologies, mAbs are mono-specific, can be generated as a constant 
resource, and therefore useful for development of standardized immunoassays. In our laboratory, 
we have previously successfully developed a species-specific mAb against S. chartarum that 
recognizes conidia but not the hyphae (11, 13, 14).  
To characterize stachylysin, we used S. chlorohalonata, a newly identified species that 
has the same phenotypic features as S. chartarum chemotype A, but morphologically is 
characterized by green extracellular pigmentation on Czapek yeast autolysate (CYA) medium (1, 
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15). The strain of S. chlorohalonata (ATCC 201863; IBT 9825) was chosen because it was used 
in previous studies to produce the stachylysin (7). It was originally designated S. chartarum and 
isolated from the home of an infant diagnosed with IPH (5, 7). Nearly all strains of S. 
chlorohalonata produce S. chartarum chemotype A toxins, atranones and dolabellanes (15). 
Atranones also contribute to a variety of immunotoxic, inflammatory and pathological changes 
on exposure of animals to conidia from S. chartarum chemotype A (16). Dolabellanes are C24 
atranones that also have been previously reported to be cytotoxic (17).  
In this chapter, we report the generation of IgM mAbs to a stachylysin preparation and 
characterize their reactivity to purified stachylysin and extracts of S. chlorohalonata. In addition, 
we characterize the mAbs for cross-reactivity to other fungal species including multiple 
Stachybotrys species. 
 
2.2 METHODS AND MATERIALS 
2.2.1 Semi-purified cytolytic Stachybotrys preparation- Stachylysin from Stachybotrys 
chlorohalonata ATCC 201863 (American Type Culture Collection, Manassas, VA) was semi-
purified from tryptic soy broth (TSB, Becton Dickinson, Sparks, MD) CSN as previously 
described (7). Briefly, S. chlorohalonata conidia (1 x 10
5
) were used to inoculate 500 ml of TSB 
in a 1 liter flask placed on an incubator shaker for 7 days (7). Cellular debris was removed from 
the TSB CSN by centrifugation for 15 minutes at 5000 g. The supernatant was then centrifuged 
in a Millipore Centricon plus 80 filter apparatus (Millipore, Bedford, MA) with a molecular mass 
cutoff of 50 kDa at 4000 g for 15 minutes. The concentrate was then subjected to gel filtration 
and fractions were collected and plated onto sheep blood agar to determine hemolytic activity as 
previously described (7). The five most hemolytic fractions were pooled, desalted, and 
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lyophilized as previously described (7). The lyophilized pellet was resuspended in sterile water 
and stored at -20°C for further analysis and for immunization of animals for antibody production.   
 
2.2.2 Preparation of fungal hyphal extracts- Fungi were grown in standard unsealed Petri 
plates containing 5 ml of malt extract agar (MEA; 2% dextrose, 0.1% peptone, 2% malt extract, 
2% agar; Difco, Becton Dickinson, Sparks, MD). After 2 weeks of incubation at room 
temperature (RT), conidia were collected from sporulating cultures into TSB and 10 ml of the 
conidial suspension (1 x 10
6
) were transferred into a 125 ml Corning flask containing 50 ml of 
TSB. The flasks were rotated at 120 rpm at 37°C for 3-4 days before the hyphae were harvested 
by filtration using a cell strainer (70 µm, Becton Dickinson). The collected hyphae were washed 
two times in 50 ml phosphate-buffered saline pH 7.4 containing 0.05% (v/v) Tween 20 (PBST) 
before being homogenized in the cell strainer using the plunger from a 10 ml syringe. The 
homogenate was centrifuged at 4100 g for 5 min at 4°C and aliquots of the supernatants were 
stored at -80°C. The total protein concentration in the hyphal extracts was determined using a 
BCA™ protein assay kit (Pierce, Rockford, IL).  
 
2.2.3 Production of monoclonal and polyclonal antibodies against stachylysin- Five 10-14 
week old BALB/c female mice were housed under controlled environmental conditions in 
HEPA-filtered ventilated polycarbonate cages on autoclaved hardwood Beta-chip bedding and 
were provided Teklad 7913 rodent chow (Harlan Laboratories, Madison, WI) and autoclaved tap 
water ad libitum. Sentinel mice were free of viral pathogens, parasites, mycoplasma, and 
Helicobacter spp. The National Institute for Occupational Safety and Health (NIOSH) animal 
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facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International (AAALAC).  
Mice were immunized intraperitoneally at bi-weekly intervals. Mice were primed with 50 
µg of stachylysin emulsified in equal volumes of TiterMax® (TiterMax USA Inc., Norcross, 
GA). The antigen concentration was reduced by half for each of 5 subsequent booster 
immunizations. A final boost of 50 µg was given three weeks after the sixth immunization and 
mice were sacrificed 3 days later for hybridoma production.  
Hybridomas were produced by standard polyethylene glycol-based cell fusion techniques 
using SP2/0-AG14 myleoma cells (ATCC# CRL-1581). Cell cultures were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, Rockville, MD), 
supplemented with 1 mM sodium pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin, 
0.292 mg/ml L-glutamine, 100 mM sodium hypoxanthine, 16 mM thymidine, 10% fetal calf 
serum (HyClone, Logan, UT), and 100 units/ml IL-6 (Boerhinger, Mannheim, Germany). 
DMEM medium was also supplemented with azaserine for selective propagation of hybridomas. 
Positive clones were identified using 1µg/ml of the stachylysin in an indirect ELISA (see below). 
Positive colonies were cloned twice by limiting dilution and the stable hybridomas were grown 
in bulk, aliquoted, and stored in liquid nitrogen. Hybridoma CSN containing anti-stachylysin 
mAbs were stored at 4°C and used for various experimental analysis. 
Rabbit pAbs against stachylysin were custom-produced and affinity-purified by Bethyl 
Laboratories (Montgomery, TX) using standard laboratory protocols.  
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2.2.4 Screening ELISA format for the analysis of hybridoma culture supernatants- 
Hybridoma CSN were screened using an indirect ELISA as previously described (11). In brief, 
ELISA plate wells were coated with 100 µl of the stachylysin (1 µg/ml) in carbonate coating 
buffer (CCB, 60 mM sodium carbonate, 140 mM sodium bicarbonate, pH 9.6) and incubated at 
RT overnight. Wells were washed 3 times with 200 µl/well of phosphate buffered-saline 
containing 0.5% Tween-20 (PBST) for 10 min. The plates were then blocked for 1 hr at RT with 
200 µl/well of PBST containing 1% non-fat dry milk powder (PBSTM). Hybridoma CSN were 
incubated for 1 hr at 37ºC with 100 µl of mAb CSN diluted 1/5 (v/v) in PBSTM.  Bound 
antibodies were detected with 100 µl of Biotin-SP-conjugated AffiPure goat anti-mouse IgG and 
IgM secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, 
Pennsylvania) for 1 hr at 37ºC at a dilution of 1/5000 (v/v) in PBSTM.  Bound biotin was 
detected with 100 µl of alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA) by incubation for 1 hr at 37ºC at a dilution of 1/5000 (v/v) 
in PBSTM.  The reaction product was produced by incubating 100 µl per well of 4-nitrophenyl 
phosphate (Sigma, St. Louis, MO) in alkaline phosphatase substrate buffer (1 M diethanolamine, 
pH 9.5; 5 mM MgCl2) at RT and the optical density (OD) was determined at 405 nm after 30 min 
using an UltraMicroplate Reader, Model ELx800 (BIO-TEK Instruments, Inc., Winooski, 
Vermont).  Negative control values were obtained by substituting plain culture supernatant for 
mAb culture.  
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2.2.5 Capture ELISA format for the analysis of hyphal extracts- The specificity of mAbs 
was tested against hyphal extracts of 7 S. chartarum isolates, 8 isolates of other Stachybotrys 
species including S. chlorohalonata as well as 39 related and non-related fungi commonly found 
in indoor environments. All extracts were tested in a capture ELISA using rabbit anti-stachylysin 
pAbs as solid-phase capture reagent. In brief, ELISA plate wells were coated with 100 µl of 
rabbit anti-stachylysin pAbs (1 µg/ml) in CCB overnight at RT. The plates were washed and 
blocked as described above and 100 µl/well of hyphal extract from each fungus (50 µg/ml) in 
PBST were added and allowed to react for 1 hr at 37°C.  After washing the plates, mAb CSNs 
diluted 4 fold in PBST were incubated for 1 hr at 37°C and the plates were processed as 
described for the screening ELISA. The ODs of supplemented DMEM that served as negative 
control ranged from 0 to 0.06. An OD ≥ 0.2 (negative control + 3 standard deviations) was 
considered to be a positive result. The sensitivity of the mAbs was measured with the same 
capture ELISA format except that the pAb was used at 2 µg/ml and the mAb CSN were diluted 5 
fold. 
 
2.2.6 Western Blot analysis of mAb reactivity- Stachylysin preparation was separated by 
SDS-PAGE on a 10% acrylamide gel and transferred to nitrocellulose membranes (BioRad, 
Hercules, CA). The membranes were blocked with 3% bovine serum albumin (BSA) for 1 hr at 
RT and incubated with mAbs (diluted 1/5 in PBST) for 1 hr at RT.  After incubation for 1 hr 
with a 1/5000 (v/v) dilution of biotin-conjugated goat anti-mouse IgM antibodies (Jackson 
Immuno Research Laboratories Inc., West Grove, PA) the membranes were incubated with 
alkaline phosphatase-conjugated streptavidin (1/5000) (v/v) for 1 hr at RT. Blots were developed 
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with the nitroblue tetrazolium and bromo-chloro-indolyl phosphate substrate (NBT/BCIP) 
(Promega, Madison, WI). 
 
2.2.7 Fluorescent halogen immunoassay- S. chartarum conidia, phialides, and hyphae were 
aerosolized by directing a jet of air across 2-week old sporulating cultures grown on MEA 
medium. Aerosolized particles were collected by suction onto mixed cellulose ester (MCE) 
protein-binding membranes (0.45 µm pore size; Millipore Corporation, Bridgewater, MA) and 
immunostained using the fluorescent halogen immunoassay (FHIA) as previously described (13). 
Briefly, a clear adhesive and glass coverslip was used to laminate samples and the antigens were 
extracted in 0.2 M borate buffer, pH 8.2 at RT for 3 hrs. The samples were blocked with 5% 
BSA in PBS pH 7.4 for 90 mins and then incubated overnight at 4ºC with the mAb 6D4 diluted 
1/50 (v/v) in PBST containing 5% BSA (PBSTB). Negative control treatments were processed in 
parallel by substituting the mAbs with supplemented DMEM medium diluted 1/50 (v/v) or 
isotype control mAb 1B9 (IgM) diluted 1:50. The membranes were rinsed 3 times in PBST and 
incubated for 90 mins with Alexa Fluor® 488-conjugated goat anti-mouse IgM (Molecular 
Probes Inc., Eugene OR) diluted 1/500 (v/v) in PBSTB. The membranes were rinsed 3 times in 
distilled H2O and mounted on a microscope slide in ProLong® Gold antifade reagent (Molecular 
Probes Inc.). Confocal laser scanning images were captured using a Zeiss LSM 510 laser 
scanning confocal system (Carl Zeiss Inc., Thornwood, NY). The images of mAb-labeled fungal 
particles were captured using 488-nm excitation and a narrow emission filter bandwidth (505-
550 nm). Fluorescent and differential interference contrast images (DIC) were captured using 
Zeiss software version 3.2 (Carl Zeiss Inc., Thornwood, NY). All settings on the confocal laser 
microscope remained constant in the analysis. 
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2.3 RESULTS 
2.3.1 mAb reactivity to S. chlorohalonata stachylysin and extracts- Immunization with 
stachylysin resulted in the production of eight murine IgM isotype antibodies (3C3, 6D4, 7D11, 
9G6, 24D11, 27C10, 27E2, and 29E5). The mAbs 3C3, 6D4, 7D11, and 9G6 were selected 
based on preliminary studies of reactivity to S. chlorohalonata extracts. These antibodies showed 
varying degrees of reactivity towards stachylysin preparation (Fig. 2.1a). mAbs 7D11, 3C3, and 
6D4 showed highest reactivity, while mAb 9G6 showed the lowest reactivity. The same pattern 
of mAb reactivity was also found against the hyphal extract of S. chlorohalonata when analyzed 
by capture ELISA (Fig 2.1.b). Reduced reactivity was observed to conidial extracts compared to 
hyphal extracts.  
 
2.3.2 Localization of stachylysin in S. chlorohalonata- To determine the localization of 
stachylysin in morphological structures of S. chlorohalonata, we used the FHIA to 
ultrastructurally locate the antibody binding sites of mAb 6D4 in S. chlorohalonata conidia and 
hyphae (Fig. 2.2). mAb 6D4 immunostaining was primarily localized around phialides and 
sterigmata (Fig. 2.2b) with highest staining primarily localized around hyphal septal junctions 
and hyphal branch points (Fig. 2.2c). In contrast, the staining of S. chlorohalonata conidia was 
less intense and mostly restricted to the surface of the conidia (Fig 2.2a). We did not observe any 
specific staining with DMEM medium control or 1B9 IgM isotype control antibody staining 






Fig. 2.1a. mAb reactivity against the stachylysin protein preparation. Stachylysin from S. chlorohalonata was 
diluted in PBSTM and the reactivity of mAbs 3C3, 6D4, 7D11 and 9G6 were analyzed by capture ELISA. Optical 
densities (OD) were measured at 405 nm after 30 mins incubation with substrate. 
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Fig. 2.1b. Reactivity of the 4 mAbs against S. chlorohalonata conidial and hyphal extracts. Extracts from conidia 
or hyphae of S. chlorohalonata were analyzed with mAbs 3C3, 6D4, 7D11 and 9G6 using the capture ELISA. 





Fig. 2.2. Fluorescent halogen immunostaining of S. chlorohalonata. a) Conidia b) Phialides c) Hyphae. Green 
dots represent AlexaFluor®488 staining to identify the localization of mAb 6D4 specific antigens in the distinct 
morphological structures of S. chlorohalonata. White arrows highlight the regions of hyphal branch bifurcation 





2.3.3  Cross-reactivity- Hyphal extracts obtained from 48 different fungal species were tested 
in the capture ELISA for cross-reactivity with the 8 different mAbs. This included hyphal 
extracts from 7 different strains of S. chartarum as well (Table 2.1). All mAbs exhibited varying 
reactivity to most of the S. chartarum strains tested here. However, mAb 29E5 failed to react 
with 4 of the 7 (57%) S. chartarum strains. All mAbs demonstrated limited cross-reactivity with 
different species of the genus Stachybotrys. The most frequent cross-reactivity was observed 
with S. chartarum, S. bisbyi and S. parvispora. However, none of the mAbs reacted with hyphal 
extracts of S. albipes, S. kampalensis or S. oenanthes. mAbs 27E2 and 29E5 did not react with 
hyphal extracts derived from S. chlorohalonata. mAb 7D11 strongly reacted to hyphal extract of 
S. cylindrospora while mAbs 27E2 and 6D4 exhibited cross-reactivity to S. nephrospora. mAbs 
7D11, 9G6, and 27E2 also displayed minimal cross-reactivity with Memnoniella echinata; a 
species that is phylogenetically related to S. chartarum. mAbs 9G6 and 27E2 also cross-reacted 
with M. subsimplex. No cross-reactivity was observed with any of the other 39 tested fungal 
species. 
 
2.3.4 Western blot- Western blot analysis following SDS–PAGE of S. chlorohalonata hyphal 
extracts indicated that the mAbs recognized multiple bands. mAbs 3C3, 7D11 and 6D4 
recognized two doublet bands at ~ 30 kDa and single band at ~ 48 kDa (Fig 2.3), while mAb 
9G6 recognized a streak of high molecular bands. Since, the antibodies were cloned by limiting 
dilution; the antigens identified by these antibodies may be highly processed proteins or possibly 
























IBT 7711 1.886 1.806 2.411 1.841 1.419 1.285 0.519 0.187 
Stachybotrys 
chartarum 
IBT 9460 1.888 1.636 2.185 1.717 1.302 1.511 0.437 0.241 
Stachybotrys 
chartarum 
IBT 9466 1.572 1.484 0.307 1.649 0.925 1.932 0.736 0.399 
Stachybotrys 
chartarum 
IBT 9631 1.307 1.149 1.537 1.499 0.598 1.241 0.591 0.356 
Stachybotrys 
chartarum 




















































2.156 2.332 3.355 0.017 1.528 2.768 0.008 0.004 







0.107 0.103 0.043 1.099 0.057 0.090 0.346 0.130 
Aspergillus 
chevalieri 






























0.023 0.014 0.053 0.087 0.021 0.054 0.027 0.015 
Aspergillus 
repens 










0.019 0.016 0.056 0.058 0.041 0.095 0.028 0.025 
Aspergillus ustus NRRL 
275 









































0.046 0.039 0.064 0.091 0.034 0.088 0.053 0.044 
Wallemia sebi NIOSH 
26-41-01 








































0.009 0.025 0.015 0.035 0.003 0.036 0.018 0.007 
Botrytis cinerea ATCC 
11542 




















0.008 0.007 0.026 0.015 0.046 0.037 0.015 0.012 

















0.083 0.047 0.087 0.057 0.102 0.131 0.076 0.060 
 
Table 2.1. Cross-reactivity profiles of the eight IgM anti-stachylysin mAbs analyzed by the capture ELISA. 
Optical densities (OD) were measured at 405 nm after 30 mins incubation with substrate. Bolded values identify 
reactivity of mAbs (columns) against a particular species (rows). ATCC- American Type Culture Collection, 
NRRL- Agricultural Research Service Culture Collection, NIOSH- National Institute for Occupational Safety 
and Health, FGSC- Fungal Genetics Stock Center, UAMH- University of Alberta Microfungus Collection and 
Herbarium, Penn State- Pennsylvania State University, IBT- Instituttet for Bioteknologi, Denmark, CBS- 




Fig 2.3. Western blot reactivity patterns: Mycelial extract from S. chlorohalonata were developed in Western blot 
analysis using Lane 1- mAb 3C3, Lane 2- mAb 6D4, Lane 3- mAb 9G6 and Lane 4- mAb 7D10. Reactive bands 




The fungal genus, Stachybotrys, is a tertiary colonizer of moisture infiltrated cellulose-
based building materials (18) and an indoor air contaminant (19). Personal exposure to 
Stachybotrys conidia has been associated with respiratory disease (5, 20-25); however, the 
scientific basis is not fully understood.  
The identification of Stachybotrys in indoor environments requires macroscopic and 
microscopic identification of conidia by a certified indoor air quality professional. A few studies 
have developed strategies aimed at detection of Stachybotrys and associated biomarkers to 
determine exposure (9, 11, 13, 14, 26-32). Often, mycological expertise is required to confirm 
the presence of Stachybotrys conidia in indoor environments, however, morphologically 
indiscernible hyphae and fragments that are equally important biomarkers of contamination, 
remain overlooked and are not quantified (33). Given the presence of Stachybotrys hyphae and 
hyphal fragments in indoor air samples and the potential health effects associated with personal 
exposure, the development of mAbs that recognize this overlooked fraction is an important step 
that will improve the quantification of these particulates. Fragments derived from hyphae and 
conidia also contain mycotoxins and other immunostimulatory antigens (34), however, the health 
effects associated with personal exposure remain uncharacterized. Recent developments in 
molecular and immunodiagnostic detection methodologies have improved the detection and 
quantification of S. chartarum. These studies have provided new insight into potential 
biomarkers of personal exposure (11, 20, 26, 27, 29) including the cytolytic protein, stachylysin 
(9, 30, 35, 36). 
 Recently, several laboratories have developed mAbs towards S. chartarum (32, 37). The 
utility of antibody-based immunoassays for the quantification of personal exposure to S. 
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chartarum has been explored elsewhere (9). A pAb has been utilized in an indirect ELISA for 
the quantification of stachylysin in environmental samples. Stachylysin has been detected in the 
serum of S. chartarum exposed animals. Similarly, stachylysin has also been detected in pooled 
serum derived from S. chartarum exposed workers but not in control subjects that had no a 
priori S. chartarum exposure (9). Although polyclonal antibodies have been developed against 
other S. chartarum exoantigens for indoor environment exposure assessment studies, pAbs often 
lack specificity and cross-react with other fungal species (9). To the best of our knowledge, 
mAbs that recognize Stachybotrys hyphae have yet to be developed.   
Though the protein sequence of stachylysin is currently unavailable, the amino acid 
composition was reported using an amino acid analysis service at Yale University (7). Amino 
acid composition similarity search using AACompIdent with ‘hemolysis’ as a key word 
identified amino acid composition similarities to hemolytic proteins from different species 
(APPENDIX A1).  
In the present study, we immunized mice with stachylysin preparation purified from S. 
chlorohalonata hyphal CSN. Eight anti-stachylysin IgM isotype mAbs were produced that 
exhibited reactivity to the original stachylysin preparation used for immunization. Four mAbs, 
that consistently showed greater reactivity toward hyphal extracts derived from S. 
chlorohalonata and S. chartarum species, were selected for further characterization. Previously, 
it was shown that hyphae contain higher levels of this hemolytic protein than the conidia and this 
observation was consistent for all strains studied (9). We have experimentally confirmed this 
earlier observation in this study where we found high concentrations of stachylysin in hyphae 
compared to conidia.  
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Immunolocalization studies utilizing the FHIA, confirmed that the greatest reactivity of 
the mAbs were toward antigens released from phialides and hyphae compared to conidia. Almost 
all reactivity in hyphae was observed at septal junctions and branch points of hyphal bifurcation. 
At this point in time it is difficult to suggest any possible role for stachylysin located at these 
points of growth. mAb 1B9, which served as an IgM isotype control in this study, was previously 
developed in our laboratory against particulate fraction of homogenized Aspergillus versicolor 
conidia (12). 
Recent taxonomic studies have segregated S. chartarum into two separate chemotypes, 
based on the production of metabolites (15, 38). Chemotype A comprises atranone and 
dolabellane producing strains (IBT 9466, IBT 9633, IBT 14915) and chemotype S consists of 
satratoxin and other macrocyclic trichothecene producing strains (IBT 7711, IBT 9460, IBT 
9631, IBT 14916). In the present study, all mAbs with the exception of mAb 29E5, reacted to 
antigens released from both chemotype A and S strains. mAbs 7D11, 9G6, and 27E2 that were 
developed in this study identified S. chlorohalonata and did cross-react with closely related 
species belonging to the genus Memnoniella. Also, our mAbs could not clearly differentiate 
between S. chartarum and S. chlorohalonata. Recent studies showed that other commercially 
available detection methodologies could also not differentiate between S. chartarum and S. 
chlorohalonata (39). Antibodies of IgM isotype can show high cross-reactivity due to the 
pentameric nature of the antibody, which contributes to increased avidity to the epitope. 
Development of IgG isotype antibodies to stachylysin may help overcome some of the cross-
reactivity problems. The reduced cross-reactivity observed for anti-stachylysin mAbs compared 
to the mAbs previously produced in our laboratory against Penicillium brevicompactum and A. 
versicolor could be due to the source of the antigen. (10, 12) Conidial antigens are fewer and 
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may be shared between various fungal species and may show less antigenic variation compared 
to hyphal antigens, which are diverse and present in larger quantities. We have observed similar 
results in Aspergillus versicolor, where mAbs produced against conidia were cross-reactive (12). 
The stachylysin preparation used in these studies was previously characterized as a 
homogenous protein preparation of ~ 12 kDa which migrates as ~ 30 kDa protein in SDS-PAGE  
(7). Interestingly, we observed immunoreactivity of the mAbs to multiple bands in Western blot 
including a doublet band at ~ 30 kDa. This suggests that mAbs recognize the epitopes on 
oligomers or higher molecular weight protein complexes covalently bound to stachylysin. Since 
hemolysins conceptually aggregate after binding to their target and not in solution, it is possible 
that the mAbs may have been generated against higher molecular weight protein complexes 
present in S. chlorohalonata.  
 In this study, four IgM monoclonal antibodies have been developed directed against 
stachylysin derived from S. chlorohalonata and partially characterized. Although the mAbs 
showed limited reactivity with conidia, the results demonstrate the potential utility of these mAbs 
for the development of immunodetection methods for the quantification of Stachybotrys hyphae 
in indoor environments. 
 In this initial attempt to study fungal hemolysins as potential biomarkers we chose 
stachylysin due to its association to IPH and clinical disease exposure. Collectively, our data 
suggest the possibility of multiple proteins in the stachylysin preparation. This makes it difficult 
to develop mAbs to study the role of a single protein using these preparations. Additionally, the 
genome for Stachybotrys has not been sequenced, which would have aided in better 
characterization of stachylysin using recombinant techniques. Also, IgM antibodies are not ideal 
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for developing immunoassays. Overall, the study was disappointing in that we were unable to 
identify the stachylysin protein with biochemical features of a hemolysin. 
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Aspergillus terreus and first approach at development of mAbs to 
putative hemolysin and its characterization 
 60
3.1 INTRODUCTION 
Aspergillus terreus was chosen because the genome was sequenced and a putative 
hemolysin was identified (1). A. terreus is one of the 4 major species including A. fumigatus, A. 
flavus and A. niger that are involved in invasive aspergillosis in humans. A. terreus-related 
invasive infections have been reported with highest mortality rates compared to other Aspergillus 
species. One of the contributing factors for high mortality is the resistance of A. terreus to the 
first line of treatment. Currently, there is a need for species-specific diagnostics for improved 
treatment strategies.  
Previously, asp-hemolysin of A. fumigatus was detected in tissues of exposed 
experimental animals (2). This generated an interest in characterization of the hemolysin of A. 
terreus and developing it as a biomarker. Observations on hemolytic activity of 50 different 
fungal species cultivated on sheep blood agar (SBA) were reported in the former study. Thirty-
five of 50 different fungal species tested exhibited hemolytic activity between days 1-5 of 
growth. Interestingly, Aspergillus terreus was one of the only 2 fungi and the only member of 
genus Aspergillus to show hemolysis after 1 day of culture.  
Our aim was to develop monoclonal antibodies (mAbs) to hemolytic protein of A. terreus 
by purifying it with methods described earlier for purification of stachylysin (3). Our goal was to 
develop species-specific mAbs recognizing A. terreus hemolysin for development of 
standardized rapid detection assays. This chapter describes A. terreus, its role in our 
environment, industrial uses and its emergence as a pathogen. Later we characterize the 
development of mAbs to purified hemolytic proteins from A. terreus.  
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3.2 ASPERGILLUS SPECIES 
Aspergillus species were first identified by a Roman Catholic clergyman and biologist 
Pier Antonio Micheli in the year 1729 (4). He identified microscopic structures bearing spores as 
being similar to ‘asperges’, which is a device used to sprinkle holy water. Aspergillus species are 
very common and pervasive. At present, over 600 species of Aspergillus have been identified 
however, with recent developments in molecular identification techniques, new species are 
routinely identified (5-8). Aspergillus species are divided into 8 different sub genera (Appendix 
A2). 
Aspergillosis is the disease state identified by infection with members of Aspergillus 
species. Infections involving fungi have been reported more frequently and Aspergillus species 
are the most common fungi associated with invasive fungal diseases in immunocompromised 
patients (9-12). Though more than 40 species of Aspergillus have been identified as medically 
relevant; Aspergillus fumigatus, Aspergillus terreus, Aspergillus niger and Aspergillus flavus are 
most frequently isolated (13). Additional species including Aspergillus clavatus and Aspergillus 
nidulans are increasingly being identified in invasive infections (14). Although 
immunosuppression is a major prerequisite to invasive infection, some conditions in otherwise 
immunocompetent individuals may predispose them to Aspergillus infections (15). Recent 
reports have also emerged on pulmonary invasive aspergillosis after H1N1 infection (16, 17).   
Aspergillus species cause diverse infections inversely associated to the status of host 
immune system (18). Pulmonary infection is often initiated by inhalation of metabolically 
dormant conidia. Owing to their small size, conidia can reach deep within the lungs in the 
alveoli. If the conidia germinate, the hyphae grow and demonstrate vasculotropic growth 
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resulting in invasion of local blood vessels, causing obliteration of host tissue and leads to 
pulmonary hemorrhage (13). 
 
3.3 ASPERGILLUS TERREUS 
 Aspergillus terreus was first described by Thom and Church in 1918 (19). A. terreus gets 
its name from the cinnamon brown (terrestrial) color of the colonies. Though colonies are 
predominantly brown, slight variations may occur between strains and may be attributed to 
differences in sporulation by individual strains (20). It plays an important role in nature in 
recycling of nutrients by decomposition of compost and plant material (21). In industry, it is used 
as a source of mevinolin (lovastatin) the first statin approved by FDA, which helps in lowering 
serum cholesterol (22-24). A. terreus is also a valuable source for various industrial chemicals 
and enzymes such as itaconic acid, gluconic acid, xylanases and proteases (25-29). A. terreus 
produces enzymes that are useful in biodegradation of lignocellulosic waste, plastics etc. (29-35). 
A. terreus conidia are 1.5-2.4 µm in diameter and spherical in shape with striations on the 
surface (20). Conidiophores are smooth hyaline structures with vesicles at the apex bearing 
conidia on phialides. A. terreus produces accessory conidia that form laterally on hyphae.  These 
accessory conidia, called aleurioconidia, are produced by the vegetative hyphae under 
submerged conditions and have been observed in vitro as well as in vivo (20). Some have 
speculated that aleurioconidia are involved in dissemination of the fungus during infection (36-
38). In comparison to phialidic conidia, aleurioconidia are larger in size, metabolically more 
active, possess enhanced adherence, and germinate very rapidly (37). All strains of A. terreus, 
clinical as well as environmental produce aleurioconidia, however variations in number and size 
exist (37). There is also a difference in the number of aleurioconidia borne at a single locus (37, 
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39, 40). Other Aspergillus species that are closely related to A. terreus, such as A. flavipes, A. 
carneus and A. niveus have also been reported to also produce aleurioconidia (36, 38).  
An increasing number of cases of aspergillosis involving A. terreus have been reported in 
recent years (20, 41-43). The same growth competences that make Aspergillus species excellent 
agents of decomposition of organic materials also make them formidable opportunistic 
pathogens. The ability of the pathogen to grow optimally at 35-37°C and its ability to tolerate 
higher temperatures (40-42°C) allows it to grow at internal body temperature that is inhibitory to 
many fungi (44, 45).   
A. terreus can cause wide range of diseases from superficial infections to invasive and 
disseminated aspergillosis. A. terreus has been identified as the causative agent in otomycosis 
(46-48), onychomycosis (49-51), endophthalmitis (52-54), cutaneous infection (55-57), 
peritonitis (58-60), osteomyelitis (61-63), allergic bronchopulmonary aspergillosis (64-66), 
aspergilloma (67, 68), and invasive aspergillosis (IA) (41, 42). A. terreus pathogenesis is poorly 
understood, however secondary metabolites that may have toxic effects on host cells have been 
reported (69-71). 
Species-specific diagnosis of A. terreus opportunistic infections is clinically important 
due to the pathogen’s resistance to the primary antifungal therapeutic amphotericin B (72-74). To 
date, the identification of A. terreus infections has challenged the most seasoned clinicians (75). 
Clinical diagnosis of A. terreus infection is subjective and has been restricted to macroscopic and 
microscopic characterization of tissue samples (76), computed tomography imaging (77), and 
detection of serum galactomannan or (1,3)-β-D-glucan (78, 79). These diagnostic methods are 
not specific and prevents the identification of the causative agent (79). Other more specific 
molecular methods such as PCR have been recently developed but are limited by a number of 
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confounding factors such as problems with consistent DNA recovery and interference by 
inhibitors of PCR process (79, 80). Due to increasing A. terreus infections reported in the 
literature, its resistance to amphotericin B, and the high mortality rate associated with infection, 
it is critical to develop sensitive and specific diagnostic tests (41).  
In this chapter, we describe the production and characterization of species-specific mAbs 
to a partially purified cytolytic A. terreus preparation (cAtp). Using the mAbs, we characterized 
the cross-reactivity profiles, kinetics of antigen expression, and detection of antigens in presence 
of human serum proteins. Collectively, these results suggest that anti-cAtp mAbs may be useful 
for immunodiagnostic assays to detect invasive A. terreus disease.   
 
3.4 MATERIALS AND METHODS 
3.4.1 Preparation of cAtp and polyclonal antibodies- A. terreus ATCC 1012 (American 
Type Culture Collection, Manassas, VA) conidia were inoculated in Tryptic Soy Broth (TSB), 
grown in liquid culture for 7 days. cAtp was partially purified from TSB using molecular sieve 
and gel filtration steps to isolate the cytolytic fraction as previously described (3). Polyclonal 
antibodies (pAbs) to cAtp were generated in rabbits by Bethyl Laboratories (Montgomery, TX) 
and affinity purified using cAtp immobilized on activated sepharose columns.  
 
3.4.2 Production of monoclonal antibodies (mAbs) to cAtp- Four 10-14 week old BALB/c 
mice (The Jackson Laboratory, Bar Harbor, ME) were housed under controlled environmental 
conditions in HEPA-filtered ventilated polycarbonate cages on autoclaved hardwood beta-chip 
bedding. Mice were provided Teklad 7913 rodent chow (Harlan Laboratories, Madison, WI) and 
autoclaved tap water ad libitum. Sentinel mice, housed in the animal quarters were free of viral 
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pathogens, parasites, mycoplasma, and Helicobacter spp. The animal protocol was approved by 
the National Institute for Occupational Safety and Health (NIOSH) Animal Care and Use 
Committee (ACUC) and the NIOSH animal facility is accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC).  
Mice were immunized (6 times) intraperitoneally at bi-weekly intervals using 25 µg of 
cAtp emulsified in TiterMax® adjuvant (TiterMax USA, Norcross, GA). Mice received a final 
boost (7
th
 immunization) of 25 µg of HEA without adjuvant 3 days before hybridoma production. 
Pre- and test-bleed mouse IgG-specific titers to HEA were tested using an indirect ELISA 
method. Briefly, 96-well Nunc Immuno MaxiSorp microplates (Thermo Fisher Scientific, 
Rochester, NY) were coated with 0.1 µg/well cAtp in carbonate coating buffer (CCB, 60 mM 
sodium carbonate, 140 mM sodium bicarbonate, pH 9.6).  Antibody binding from mouse sera 
was determined using biotin-SP goat anti-mouse IgG Fcγ (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA) and alkaline phosphatase (AP)-conjugated Streptavidin 
(Jackson ImmunoResearch Laboratories Inc.). ELISA plates were developed with 4-nitrophenyl 
phosphate substrate (Sigma, St. Louis, MO) and read at 450 nm after 30 mins as previously 
described (81). 
Three days following the final boost, the immunized mice were euthanized by CO2 
asphyxiation, the spleens were surgically removed, and splenocytes were fused with SP2/0-Ag 
14 ATCC myeloma cells (ATCC# CRL-1581). Hybridomas were selected by growing the cells 
in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, Rockville, MD) 
supplemented with 1 mM sodium pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, 
0.292 mg/mL L-glutamine, 100 mM sodium hypoxanthine, 16 mM thymidine, 10% fetal calf 
serum (FCS) (HyClone, Logan, UT), and 100 U/mL IL-6 (Boehringer, Mannheim, Germany). 
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DMEM medium was also supplemented with azaserine for selective propagation of hybridomas. 
After 10-14 days of hybridoma cell growth, the medium from individual wells was replenished 
with fresh medium. The tissue culture supernatant (CSN) fluid from individual hybridoma 
colonies was tested using a modification of a previously described sandwich ELISA. CSN from 
individual hybridoma clones was tested in duplicate to confirm the presence of cAtp-specific 
mAbs. Each positive hybridoma clone was further cloned twice by limiting dilution and single 
positive clones were screened and selected for bulk mAb production. Hybridoma cell lines of 
individual clones were frozen in FCS containing 10% dimethyl sulfoxide (DMSO) and stored at -
80°C for 2 weeks, and then transferred to a liquid nitrogen tank for long term storage. 
 
3.4.3 cAtp capture ELISA- In brief, 96-well Nunc Immuno MaxiSorp microplates (Thermo 
Fisher Scientific, Rochester, NY) were coated with 100 µl/well rabbit anti-cAtp polyclonal 
antibody (pAb) (1 µg/ml) in CCB and incubated overnight at RT. Wells were washed three times 
by incubating with 200 µl/well of PBS containing 0.05% Tween 20 (PBST) for 10 min. The 
plates were then blocked for 1 h at RT with 200 µl/well of PBSTM (PBST containing 1 % non-
fat dry milk powder).  Wells were then incubated for 1 h at 37
o
C with 100 µl/well cAtp (1 µg/ml) 
to bind cAtp. Plates were then processed with hybridoma CSN, followed by goat anti-mouse IgG 
antibody as described above. Negative control values were obtained by substituting hybridoma 
CSN with supplemented DMEM. 
 
3.4.4 Isotyping and quantification of IgG antibodies- Isotyping of individual mAbs was 
determined by a direct ELISA. Plates were coated with CSN from A. terreus diluted in CCB (1 
µg/ml) and incubated overnight. Next day plates were blocked with PBSTM and incubated with 
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mAb solutions from individual hybridomas. mAbs bound to cAtp antigens were detected using 
Biotin SP-conjugated AffiniPure goat anti-mouse IgG1, IgG2a, IgG2b and IgG3 secondary 
antibodies (Jackson ImmunoResearch Laboratories Inc.) at a dilution of 1:5000 in PBSTM. 
ELISA plates were developed using methods described earlier.  
For quantification, mAbs were serially diluted and captured on ELISA plates coated with 
AffiniPure goat anti-mouse IgG, Fc fragment of either subclass 1, 2a, 2b or 3 specificity at 1 
µg/ml concentration depending on the isotype of the mAb to be quantified (Jackson 
Immunoresearch Laboratories Inc.). IgG1, IgG2a, IgG2b and IgG3 standards (Sigma) were used to 
set up a standard curve for quantification purposes. AP-conjugated goat anti-mouse secondary 
antibodies (1:5000) diluted in PBSTM were used for quantification experiment. 
 
3.4.5 Preparation of A. terreus extracts for characterization of mAbs- Conidial extracts. 
Conidia were collected from 10-14 days old A. terreus cultures grown on Malt Extract Agar 
(MEA) by rolling approximately 1 gm of 0.5 mm glass beads (BioSpec Products Inc., 
Bartlesville, OK) over the plate. Glass beads with conidia were collected into a 2 mL screw cap 
microcentrifuge tube and processed in a mini bead beater (BioSpec Products Inc.). Mechanical 
bead beating was carried out for 2 mins to disrupt the outer cell wall of the conidia. Conidial 
proteins were collected in 50 mM ammonium bicarbonate buffer pH 8.0 containing 0.5 M 
ethyldiaminetetraacetic acid, 0.1 M phenylmethylsulfonyl fluoride, and cOmplete Mini Protease 
Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany). The suspension was centrifuged at 
4100 g for 10 mins and the supernatant fluid was collected and lyophilized overnight. 
Lyophilized conidial protein extract was resuspended in PBS pH 7.4 and stored at -80°C.  
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 Hyphal extracts and culture supernatants. Viable A. terreus conidia (2.5 x 10
7
 conidia) 
were inoculated in 50 mL minimal medium consisting of 1% glucose, nitric salts and trace 
elements (82). Viability of conidia was determined by LIVE/DEAD® BacLight
TM
 viability kit 
(Invitrogen, Carlsbad, CA) previously used for determination of viability of fungal conidia (83). 
Cultures were grown at RT or 37°C with shaking (200 rpm) for varying intervals of time. For 
mAb reactivity assays, cultures were grown for a period of 6 days and for the kinetics of 
expression studies, cultures were grown for up to 12 days with samples collected every 24 hrs. 
Mycelial cultures were harvested by centrifugation at 4100 g for 5 mins and the hyphae (pellet) 
and CSN were collected and concentrated by lyophilization. The lyophilized CSN was 
reconstituted in 5 mL PBS pH 7.4 containing complete Mini Protease Inhibitor Cocktail and 
stored at -80°C for further analysis. Lyophilized hyphae were macerated in a mortar containing 
liquid N2, suspended in cold PBS containing complete Mini Protease Inhibitor Cocktail, and 
incubated overnight on a rocker at 4°C to extract proteins. The mycelial extract (ME) was 
centrifuged at 4100 g for 5 mins and the supernatant fluid was collected, aliquoted and stored at -
80°C for further analysis. Protein concentrations in all fungal extract preparations were 
determined using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Thermo 
Scientific, Wilmington, DE). 
 
3.4.6 Characterization of cAtp expression in fungi- For cross-reactivity analyses, 56 fungal 
isolates representing 46 fungal species (Table 1.) were grown on MEA medium for 7-10 days. 
The conidia (1.25 x 10
8
) were collected, and inoculated into 50 mL TSB medium. Cultures were 
grown for 4 days at RT and centrifuged at 4100 g for 5 mins to collect the mycelial pellet. The 
pellet was washed 3 times with cold PBS pH 7.4, macerated, and then centrifuged at 4100 g for 5 
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mins as previously described. The supernatant fluid was collected, protein concentration 
determined by NanoDrop spectrophotometer, and mAb reactivity tested using the previously 
described capture ELISA. Positive reactivity was determined by an Optical Density (OD) of ≥ 
0.2 (negative control value + 3 standard deviations). The OD values of the negative controls 
ranged from 0 to 0.18 for different fungal extracts. 
The kinetics of antigen expression during culture was also examined. Individual mAbs 
were tested against A. terreus conidial, hyphal, and CSN extracts used at 100 µg/ml of total 
protein to determine the level of antigen expression during different phases of A. terreus growth. 
The pAb-based capture ELISA was used for this analysis and all mAbs were normalized to 500 
ng/ml in PBSTM. Plates were developed using secondary antibodies and reagents as previously 
described. 
 
3.4.7 cAtp detection in spiked human serum- Detection of cAtp antigens by the mAbs in 
presence of human serum was studied using the ELISA methods described earlier. CSN was 
collected from a 6 day culture of A. terreus and was diluted to 100 µg/ml. Pooled human serum 
(Sigma) was spiked with dilutions of A. terreus CSN and assayed in the capture ELISA at a final 
concentration of 50% total volume using 100 µl of sample. Additionally, samples were also 
incubated in PBS and served as control for this experiment. All samples including controls were 
incubated at 37°C for 1 hr before analysis in capture ELISA method. 
 
3.4.8 Western blot assay- A. terreus CSN (100 µg/ml) obtained from a 6 day TSB culture was 
separated on a 12% polyacrylamide gel using SDS-PAGE under reducing conditions. Proteins 
were transferred overnight at 30V to a 0.2 µm nitrocellulose membrane. The membrane was 
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blocked with containing 3% bovine serum albumin (BSA) in PBST (PBSTB) for 2 hrs. The 
membrane was washed in PBST and then processed using a Mini-PROTEAN II Multiscreen 
Apparatus (Bio-Rad Laboratories, Hercules, CA). Each lane on the membrane was incubated 
with an individual mAb (500 ng/ml) for 1 hr with shaking. The membrane was washed with 
PBST and incubated with AP–conjugated goat anti-mouse IgG (H+L) (Promega, Madison, WI) 
diluted 1/5000 (v/v) in PBST for 1 hr with shaking. The membrane was then washed with PBST 
and developed using 1-step NBT/BCIP substrate (Promega). The substrate reaction was 
developed for 15-20 mins and stopped by washing the membrane with distilled water. 
 
3.4.9 Immunoprecipitation of cAtp antigens using Protein G- Immunoprecipitation of 
antigens recognized by mAbs 13E11, 12C4 and 19B2 was performed using Dynabeads® Protein 
G (Invitrogen Dynal AS, Oslo, Norway) per the manufacturer’s instructions. Briefly, Protein G 
magnetic beads were washed twice with W&B buffer (0.1M Na-phosphate, 0.01% Tween 20, pH 
8.2) and incubated with 5 µg of the individual mAbs diluted in W&B buffer for 10 mins with 
rotation at RT. Antigen capture was performed after washing the Protein G magnetic beads with 
PBS and incubating with A. terreus hyphal extract overnight at 4°C. The beads were washed 
thoroughly in PBS and the immunoprecipitate was eluted with Laemmli Sample Buffer (BioRad, 
Hercules, CA) containing 2-mercaptoethanol (5% v/v). Immunoprecipitate samples were 
analyzed by SDS-PAGE and stained with Imperial
TM
 Protein Stain (Thermo Scientific, 
Rockford, IL). Bands of interest as determined by a parallel Western blot analysis were excised 
from the SDS-PAGE gels and processed for proteomic analysis. 
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3.4.10 Proteomic analysis- In gel reduction/alkylation/digestion. All reagents were obtained 
from Sigma Chemical (St. Louis, MO) unless otherwise noted. All incubations were performed 
at 37°C with shaking (300 rpm). Protein bands of interest were excised, reduced, alkylated, and 
digested with porcine trypsin according to published methodologies (84, 85). Protein bands were 
transferred to low retention, siliconized 0.5 ml microcentrifuge tubes and destained with two 
washes of 200 µl 200 mM NH4HCO3 in 40/60 acetonitrile/water for 30 mins and the supernatant 
removed. The gel bands were dehydrated 30 mins in a vacuum concentrator and rehydrated with 
200 µl 0.5 mM tributylphosphine in 25 mM NH4HCO3, followed by 15 min incubation. The 
supernatant was removed and replaced with 200 µl 0.4 mM iodoacetamide, followed by 30 min 
incubation. The gel bands were washed twice with 200 µl 25 mM NH4HCO3 for 15 mins 
followed by one wash with 200 µl 200 mM NH4HCO3 in 40/60 acetonitrile/water. Gel bands 
were dehydrated 30 mins in a vacuum concentrator and rehydrated with 1 µg porcine trypsin in 
100 µl of 50 mM NH4HCO3. The samples were allowed to digest overnight and the supernatant 
was removed to a clean siliconized microcentrifuge tube. The gel bands were washed once with 
0.1% trifluoroacetic acid in 50% acetonitrile for 15 min. The wash and digest supernatants were 
combined and concentrated for 1 hr in a vacuum concentrator and reconstituted in 20 µl 0.1% 
trifluoroacetic acid prior to LC-MS/MS analysis. 
Ultra-performance liquid chromatography/Tandem mass spectrometry. Enzymatic 
peptides were separated on a Waters (Milford, MA) nanoACQUITY ultra-performance liquid 
chromatography (UPLC) system. Aliquots (3 µl) of the digest mixture were injected and 
trapped/desalted on a 5 µm SymmetryC18 (180 µm x 20 mm) trapping column with 99.5/0.5 A/B 
(A:0.1% formic acid; B:0.1% formic acid in acetonitrile) at a flow rate of 15 µl/min for 1 minute. 
Separation was performed on a 1.7 µm BEH130 C18 (75 µm x 100 mm) analytical column 
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utilizing gradient elution at a flow rate of 300 nl/min and a gradient of 99/1 to 60/40 A/B over 60 
min. The eluent from the UPLC system was directed to the nanoelectrospray source of a Waters 
SYNAPT MS quadrupole time-of-flight (qTOF) mass spectrometer. Positive ion 
nanoelectrospray was performed utilizing 10 µm PicoTip (Waters) emitters held at a potential of 
+3.5 kV. The cone voltage was held constant at +40 V for all experiments. Dry N2 desolvation 
gas was supplied to the instrument via a nitrogen generator (NitroFlowLab, Parker Hannifin 
Corp., Haverhill, MA). [Glu]
1
-Fibrinopeptide B (100 fmol/µl in 75/25 A/B) was supplied to an 
orthogonal reference probe and the [M+2H]
2+
 ion (m/z = 785.84265u) measured as an external 
calibrant at 30 sec intervals. Ultra-high purity (UHP) argon was used as collision gas.  Spectra 
were acquired in an “MS
e
” fashion (86). Alternating one-second mass spectra were acquired. The 
collision energy was set to 6 eV (1 sec low energy scan) and a 15-30 eV ramp (1 sec high energy 
scan).  
Homology searching. Data were analyzed with ProteinLynx Global Server v. 2.4 
(Waters) using the default PLGS search engine to query a custom Aspergillus terreus database 
downloaded from UniProtKB/Swiss-Prot and UniProtKB/TrEMBL 
(http://www.uniprot.org/uniprot/?query=terreus). A minimum of 2 peptides, with a minimum of 
three fragment ions each was required for identification. Trypsin was specified as the digestion 
enzyme and 1 missed cleavage was allowed. Carbamidomethyl cysteine was specified as a fixed 
modification and oxidized methionine and phosphoryl serine, threonine, and tyrosine were 
allowed as variable modifications. Protein assignments were confirmed via manual inspection of 
tandem mass spectra. 
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3.4.11 Confocal Scanning Laser Microscopy (CSLM) analysis for localization of putative 
leucine aminopeptidase and probable dipeptidyl-peptidase V of A. terreus- 
Immunolocalization of A. terreus leucine aminopeptidase and dipeptidyl-peptidase V was 
studied using methods previously described with slight modifications (87, 88). Briefly, A. terreus 
FGSC 1156 cultures were grown on alcohol-sterilized cover slips in 6-well tissue culture plates 
containing minimal medium. Cultures were incubated at 37°C without shaking for 24 hrs.  Cover 
slips were fixed with 8% formalin buffered saline containing 50 mM PIPES (pH 6.7), 25 mM 
EGTA, 1% dimethyl sulfoxide (DMSO) and 5 mM MgSO4. Cells were fixed for 1 hr at RT and 
later rinsed with MTSB (50 mM PIPES (pH 6.7), 5 mM EGTA and 5 mM MgSO4). Cell wall 
digestion was carried out for 1 hr at RT with an enzyme solution containing 2.5% Driselase® 
(Sigma, St. Louis, MO), 1% lysozyme from chicken egg white (Sigma) and 2 mM EGTA. Cells 
were rinsed with H2O and were extracted with 0.1% Triton X-100 in Tris Buffered Saline (TBS) 
pH 7.4 for 10 mins. Cells were quickly rinsed in MTSB and TBS once each. Cells were blocked 
with 3% bovine serum albumin in TBS (TBSB) overnight at 4°C with gentle shaking. Next day, 
cover slips were incubated with mAb 9B4, 13E11 or 19B2 at 3 µg/ml in TBSB for 3 hrs with 
gentle shaking. mAb 9B4 was previously developed in our laboratory against an unidentified 
Stachybotrys chartarum conidial surface protein and is of IgG1 isotype (81). Cells were washed 
thoroughly in TBS containing 0.05% Tween 20 (T-TBS) and stained with AlexaFluor® 594 
conjugated goat anti-mouse IgG (H+L) (Molecular Probes Inc., Eugene, OR) diluted 1:50 (v/v) 
in TBSB for 1 hr at RT. Cells were washed thoroughly in T-TBS and cover slips were placed on 
clean slides with ProLong® Antifade Reagent with DAPI (Molecular Probes Inc.). Cells were 
observed with a Zeiss LSM-510 Meta Confocal Microscope System (Axioplan 2 Stand) (Carl 
Zeiss, Thornwood, NY). The images of AlexaFluor® 594 labeled secondary antibodies bound to 
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anti-HEA mAbs were acquired with Zeiss software version 3.2 (Carl Zeiss).  All settings on the 
confocal laser microscope remained constant throughout the analysis.  
 
3.5 RESULTS 
3.5.1 Characterization of mAb reactivity to fungal extracts- All 4 mice immunized with 
cAtp, developed detectable IgG response to specific antigens after 3-4 immunizations, which 
mostly stabilized by the 4
th
 immunization. Twenty-three murine IgG1 isotype hybridomas were 
developed against cAtp (Table 3.2). Since the mAbs were developed against a partially purified 
cytolytic extract, reactivity of the mAbs to A. terreus culture extract antigen was tested. The 
mAb reactivity was the highest to mycelial extracts (ME); however, weak reactivity to conidial 
extracts was also observed (Fig. 3.1a). As expected, the mAbs also showed significant reactivity 
to 6 day CSN from A. terreus cultures grown at RT and greater reactivity to CSN grown at 37°C 
(Fig. 3.1b). Collectively these results show that the mAbs react predominantly with hyphal 
antigens that are possibly actively secreted into the CSN.  
 
3.5.2 Cross-reactivity of mAbs towards different fungi- Fifty-six different isolates of 46 
fungal species representing 20 different genera were tested for cross-reactivity in the capture 
ELISA (Table 3.1). Positive reactivity was defined as a value ≥ 0.2 OD405. All mAbs showed 
reactivity to ME tested from each A. terreus strain tested in this study (Table 3.1). Of the 23 
mAbs that react with cAtp, 16 (70%) did not cross-react with any of the fungal species tested 
here (Table 3.2). Seven mAbs cross-reacted with other fungi. Most of the cross-reactivity 
observed in these 7 mAbs was limited within the genus Aspergillus except mAb 22D9 that also 
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cross-reacted with ME derived from Acremonium strictum. Five mAbs (22D9, 38B6, 40C6, 
52G7 and 64B3) cross-reacted with ME from at least 1 other fungus, while 24D7 cross-reacted 
with 2 different fungi (Table 3.2). The mAb 67G7 exhibited the greatest cross-reactivity, 
reacting to hyphal extracts derived from 4 different Aspergillus species (A. flavus, A. parasiticus, 
A. repens and A. sydowii). Of the fungal species tested, A. sydowii and A. repens ME showed 
highest cross-reactivity. 
 
3.5.3 Western blot analysis of cAtp- Western blot analysis was performed with CSN from A. 
terreus culture using the 16 species-specific mAbs and the cross-reactive mAb 67G7 (Fig. 3.2). 
The results demonstrated differences within the mAbs in their reactivity to antigens in A. terreus 
CSN. The mAbs 13E11, 19B7, 24C8, 29C9 and 61E5 showed a similar pattern with strong 
reactivity to bands at ~18 kDa, 45 kDa, and ~70 kDa bands. The mAb 19B2 identified unique 
high molecular weight bands at ~ 100 kDa and ~ 150 kDa. It is possible that the immune 
reactivity to the 10 kDa and the 45 kDa antigens is due to binding of antibodies to shared 





Fig. 3.1. mAb reactivity to A. terreus extracts. a) mAb reactivity to A. terreus conidial and hyphal extracts. 
Conidial and mycelial extracts of A. terreus were tested against 16 specific mAbs. CE- Spore extract, RT ME- 
Mycelial extract collected from an A. terreus culture grown at room temperature, 37°C ME- Mycelial extract 
collected from an A. terreus culture grown at 37°C. b) mAb reactivity to A. terreus culture supernatants. Culture 
supernatant (CSN) collected from RT CSN- room temperature and 37°C CSN- 37°C cultures of A. terreus were 
tested against 16 specific mAbs. Error bars represent the standard deviations of duplicate determinations from 
three independent experiments. 
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Fungal Species Culture 
collection 
I.D. 
Fungal Species Culture 
collection I.D. 
Aspergillus terreus ATCC 1012 Myrothecium verrucaria NRRL 2003 
Aspergillus terreus FGSC A1156 Paecilomyces variotii ATCC 66705 
Aspergillus terreus ATCC 16794 Penicillium 
aurantiogriseum 
NRRL 971 
Aspergillus terreus SRC 2174 Penicillium expansum NRRL 973 
Aspergillus chevalieri NRRL 78 Penicillium fellutanum NRRL 746 





Aspergillus flavus ATCC 24689 Penicillium roqueforti NRRL 844 
Aspergillus fumigatus FGSC A1100 Rhizopus stolonifer NIOSH 17-59-14 
Aspergillus nidulans NIOSH 15-
22-08 
Stachybotrys albipes ATCC 18873 
Aspergillus niger FGSC A1144 Stachybotrys bisbyi ATCC 18825 
Aspergillus parasiticus ATCC 26691 Stachybotrys chartarum IBT 7711 
Aspergillus repens NRRL 13 Stachybotrys chartarum IBT 9290 
Aspergillus sydowii ATCC 9507 Stachybotrys chartarum IBT 9460 
Aspergillus ustus NRRL 275 Stachybotrys chartarum IBT 9466 
Aspergillus versicolor ATCC 44408 Stachybotrys chartarum IBT 9631 
Acremonium strictum ATCC 46646 Stachybotrys chartarum IBT 9633 
Alternaria alternata ATCC 11612 Stachybotrys chartarum IBT 14915 
Alternaria brassicicola ATCC 96836 Stachybotrys chartarum IBT 14916 














ATCC 11288 Stachybotrys 
nephrospora 
ATCC 18839 
Epicoccum nigrum ATCC 34929 Stachybotrys oenanthes CBS 252.76 
Exserohilum rostratum ATCC 26856 Stachybotrys parvispora CBS 100155 
Fusarium moniliforme PS M6131 Scopulariopsis brumptii ATCC 16278 
Geotrichum candidum UAMH 7863 Stemphylium botryosum ATCC 26881 
Memnoniella echinata NRRL 2373 Trichoderma viride ATCC 16640 
Memnoniella 
subsimplex 
ATCC 32888 Wallemia sebi NIOSH 26-41-01 
 
Table 3.1. Fungal species tested for cross-reactivity of cAtp-mAbs. Designation of sources for the 54 species 
representing 20 different genera of fungi. ATCC- American Type Culture Collection, NRRL- Agricultural 
Research Service Culture Collection, NIOSH- National Institute for Occupational Safety and Health, FGSC- 
Fungal Genetics Stock Center, UAMH- University of Alberta Microfungus Collection and Herbarium, Canada, 
PS- Pennsylvania State University, IBT- Instituttet for Bioteknologi, Denmark, CBS- Centraalbureau voor 
Schimmelcultures, The Netherlands. 
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cAtp-IgG1 mAbs Cross-reactivity 
2G3, 7C9, 8G7, 12C4, 12G9, 13D9, 
13E11, 14C8, 15B11, 15D3, 19B2, 19B7, 
24C8, 29C9, 34F8, 61E5 
No cross-reactivity to any other species 
tested. 
22D9 Acremonium strictum ATCC 46646 
24D7 Aspergillus sydowii ATCC 9507, 
Aspergillus repens NRRL 13 
38B6, 40C6, 52G7, 64B3 Aspergillus repens NRRL 13 
67G7 Aspergillus flavus ATCC 24689, 
Aspergillus parasiticus ATCC 26691, 
Aspergillus repens NRRL 13, Aspergillus 
sydowii ATCC 9507 
 




Fig. 3.2. Western blot reactivity of proteins in A. terreus culture supernatant extracts using anti-cAtp mAbs. 1- 
mAb 2G3, 2- mAb 7C9, 3- mAb 8G7, 4- mAb 12C4, 5- mAb 12G9, 6- mAb 13D9, 7- mAb 13E11, 8- mAb 14C8, 9- 
mAb 15B11, 10- mAb 15D3, 11- mAb 19B2, 12- mAb 19B7, 13- mAb 24C8, 14- mAb 29C9, 15- mAb 34F8, 16- 
mAb 61E5, 17- mAb 67G7. 
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3.5.4 Kinetics of A. terreus exoantigen expression- Four mAbs (13E11, 15D3, 19B2 and 
19B7) were chosen for further study based on differences in patterns of reactivity in ELISA and 
Western blotting. Fig. 3.3 illustrates the time course of cAtp expression in A. terreus cultures. 
For mAbs 13E11, 15D3, and 19B7, the concentration of the cAtp rapidly increased in ME during 
days 3 to 5 and peaked at day 6 (Fig. 3.3a). Reactivity to cAtp in the CSN followed a similar 
pattern but appeared to lag behind ME by 24 hrs (Fig. 3.3b). At 37°C, cAtp mAb reactivity was 
readily detectable by 24 hrs in both ME (Fig. 3.3c) and CSN (Fig. 3.3d) and peaked by days 3 
and 4, respectively. Interestingly, cAtp mAb reactivity could be detected in both ME and CSN 
beyond day 6 but appeared to decline in CSN after 10 days at 37°C. The mAb 19B2 antigen, 
while having a similar pattern as the other mAbs, appeared to lag in expression suggesting that 
this mAb may recognize a different antigen compared to other mAbs used in this study. Also, we 
observed a more rapid degradation of mAb 19B2 antigen after day 10 in CSN of A. terreus 
cultures grown at 37°C. This could probably be due to proteolytic degradation of the antigen. 
 
3.5.5 Human serum detection assay- To determine the ability of these mAbs to be used in 
immunodiagnostic assays, we tested 10 mAbs for reactivity to A. terreus antigens spiked into 
human serum (Fig. 3.4). CSN grown at 37ºC was mixed with human serum and assayed using a 
capture ELISA. Overall, there was a slight reduction in the detection of cAtp when spiked into 
human serum as compared to PBS alone for all mAbs tested, however, there did not seem to be 




Fig. 3.3. Time point kinetic assay of cAtp in A. terreus hyphae and CSN. a) ME collected from A. terreus cultures 
grown at RT. b) CSN collected from A. terreus cultures grown at RT. c) ME collected from A. terreus cultures 
grown at 37°C. d) CSN collected from A. terreus cultures grown at 37°C. All samples were collected at 24 hr 







Fig 3.4. Lack of interference by serum proteins in the detection of cAtp by mAbs in presence of serum. A. terreus 




3.5.6 Immunoprecipitation and determination of protein IDs- Three mAbs (13E11, 19B2 
and 12C4) were selected for further analysis based on exhibition of differential patterns of 
reactivity to A. terreus extract (Fig. 3.2). The mAbs were incubated with the A. terreus hyphal 
extract, and protein-antibody complexes bound to the protein G magnetic beads were eluted and 
separated using SDS-PAGE. Using mAb 13E11 to stain the immunoblot showed 
immunoprecipitation of an ~ 65 kDa band, slightly higher than the antibody heavy chain band. 
Interestingly, mAb 13E11 also showed similar reactivity to immunoprecipitate of mAb 12C4 but 
not to that of mAb 19B2 (Fig. 3.5). This suggests that mAb 13E11 and mAb 12C4 recognized 
similar antigens. In contrast, mAb 19B2 demonstrated immunoreactivity to an antigen localized 
at ~ 100 kDa. While mAb 12C4 precipitated a 66 kDa band that was recognized by mAb 13E11, 
this mAb does not recognize this band when used to stain the Western blot, indicating that it may 
recognize a conformational epitope. 
 Specific bands were excised from a parallel SDS-PAGE gel on which 
immunoprecipitated samples from each mAb were separated. Samples were subjected to UPLC 
tandem (MS/MS) analysis to determine the identity of the proteins. By comparing peptide 
masses of recovered peptides in silico to the generated database for A. terreus, we identified 
peptides for a putative uncharacterized protein (Q0CAZ7) in immunoprecipitates from both 
mAbs 13E11 and 12C4. The protein Q0CAZ7 has (> 60%) sequence homology to a leucine 
aminopeptidase found in other Aspergillus species such as A. fumigatus, A. nidulans, A. oryzae 
and A. flavus. Peptides for a probable dipeptidyl peptidase V (Q0C8V9) were also identified 
following UPLC MS/MS analysis of mAb 19B2 immunoprecipitates (Table 3.3.). Both of these 
proteolytic enzymes consist of putative N-glycosylation sites and are secreted after processing of 
a signal peptide. 
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Fig. 3.5. Immunoprecipitation of cAtp antigens. mAbs 13E11, 19B2 and 12C4 were used for 
immunoprecipitation of their respective antigens from A. terreus CSN. Immunoprecipitates were analyzed using 




3.5.7 Immunolocalization of cAtp antigens- The immunolocalizations of A. terreus leucine 
aminopeptidase (mAb 13E11) and dipeptidyl peptidase V (mAb 19B2) in the hyphae were 
determined using confocal scanning laser microscopy. Interestingly, the leucine aminopeptidase 
was localized in extracellular matrix (ECM) structures (Fig 3.6). Immunostaining was also 
observed within the hyphae. mAb 19B2 immunostaining for a probable dipeptidyl peptidase V 
was diffuse but uniform over the entire hypha, suggesting that this protein might be present in 
the cytoplasm of A. terreus hyphae. No staining was observed in the extracellular matrix for 
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52% 37, 79, 97, 154, 
255, 339, 381, 
451, 509, 608 
Between 19 
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Table 3.3 Proteomic analysis of cAtp antigens. Numbers for N-Glycosylation and signal peptides sites are amino 




Fig. 3.6. Immunolocalization of cAtp antigens. Immunolocalization of HEA antigens was determined by 
AlexaFluor® 594 –labeled goat anti-mouse IgG secondary antibodies (Red) and nuclear staining was identified 




Invasive aspergillosis develops in the lungs of immunocompromised patients following 
the inhalation of viable Aspergillus conidia from the environment (13, 41, 89). Upon 
germination, the conidia differentiate into a vegetative hyphal form that can cause damage to the 
host tissue and may allow the fungus to disseminate to other parts of the body (15). To date, the 
diagnostic methods have been limited to identifying macroscopic and microscopic characteristics 
in lung biopsies (18, 79). Serological diagnostics have also been developed but are limited to the 
detection of galactomannan and (1,3)-β-D-glucan (18, 79). Although this methodology may 
confirm a fungal infection, it does not identify the specific pathogenic species involved. Previous 
studies have detected Aspergillus antigens in the sera and urine of patients diagnosed with 
invasive aspergillosis (90-93). These results suggest that during infection, Aspergillus species 
secrete proteins into the blood stream that could be detected serologically. Therefore it is critical 
to identify biomarkers that could be used serologically for the identification of individual 
pathogenic Aspergillus species.  
Although A. fumigatus is the most widely known etiological agent of invasive 
aspergillosis, A. terreus has emerged as a pathogen and can cause a variety of infections 
including fatal disseminated aspergillosis (20). To our knowledge, no immunodiagnostics have 
been developed for the specific detection of A. terreus in clinical samples. In this study, 23 IgG1 
mAbs were produced using a partially purified cytolytic cAtp preparation using a methodology 
previously used to purify stachylysin from Stachybotrys chartarum (3). The mAbs developed in 
the present study specifically detect antigens localized in conidia and hyphae, but more 
importantly, these antigens were detected in the CSN fluid. These findings demonstrate that 
these hemolytic antigens may be actively secreted during hyphal differentiation and growth and 
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may function as candidate biomarkers for immunodiagnostic assays similarly to stachylysin. 
Detection of hemolytic antigen in higher concentrations in hyphae is consistent with our previous 
studies of stachylysin described in the previous chapter and in other studies as well (3, 94-96). 
Sixteen mAbs were found to be species-specific, while seven cross-reacted with other species. 
The species-specific mAbs did not cross-react with ME from other important Aspergillus 
pathogens including A. fumigatus, A. flavus, A. niger and A. nidulans. No cross-reactivity was 
observed with other fungal species belonging to the genera Penicillium and Fusarium. Most 
cross-reactivity was minimal with OD450 values ≤ 0.5.  
Previously, differences were reported in metabolic activities, growth rate and virulence 
capabilities of different A. terreus strains depending on their environmental source (44). We 
were curious to see if any of these differences reflected in altered expression of cAtp antigens. 
All mAbs reacted with the mycelial extracts from the 4 A. terreus strains used in this study, 
however, comprehensive testing with additional clinical strains of A. terreus strains will be 
critical prior to the development of diagnostic methods for use in the clinical setting. Moreover, 
other species that are closely related to A. terreus such as A. carneus, A. niveus and the newly 
identified A. alabamensis (5) as well as other unrelated species including Scedosporium and 
Rhizopus stolonifer (11) should be tested for cross-reactivity.  
 A. terreus growth is accompanied by conidial germination during favorable nutrient and 
environmental conditions. This process involves the swelling of conidia, initiation of primary 
metabolism, and eventually hyphal extension and aggregation. In this study, we observed that the 
antigens were detected earlier in hyphal growth than in CSN suggesting an active secretion of 
these proteins. The concentration of these antigens appeared to correlate with an increase in the 
total biomass of the fungus as measured by the mycelial pellet size and protein concentration 
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(data not shown) during cAtp kinetic experiments. mAb reactivity to cAtp was also observed to 
increase progressively with increases in pellet size. Most importantly, cAtp was continuously 
detected in CSN at 37°C, emphasizing the relative stability of these antigens to proteolytic 
degradation for longer period of time.  
Detection of antigens in CSN may not fully reflect antigen production during invasive 
disease. Furthermore, secreted antigens may bind to serum proteins or other factors that alter the 
conformation of the protein and subsequently reduce the availability of the epitope for mAb 
detection. Certain fungal proteins are known to bind serum components in vitro (97). In tests 
with pooled human serum, there was only a slight reduction in detection of the epitopes using 
our mAbs. This suggests that the epitopes detected by our mAbs do not interact with serum 
components and this may have potential use for serodetection of invasive A. terreus disease.  
Leucine aminopeptidase and dipeptidyl-peptidase V are both predicted to possess 
putative N-glycosylation sites as determined by N-Glycosite (98). These proteins are secreted 
with putative signal peptides as determined by SignalP, version 3.0, in silico analysis (99-101). 
This has been confirmed experimentally by us in this study and previously by others for A. 
terreus and other fungal species (102, 103). Homologous dipeptidyl-peptidase V in other fungal 
species have been reported as a potential virulence factor or allergen and as important for tissue 
invasion and modulation of host immune responses (103-109). 
Immunolocalization studies demonstrated that the putative leucine aminopeptidase 
identified by mAb 13E11 was localized to extracellular structures containing DNA. Similar 
structures containing extracellular DNA have been very recently reported in vitro and in vivo and 
have been identified as the extracellular matrix of fungi (110-112). ECMs have been only 
recently identified and there is little information on their role in pathogenesis of fungal 
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infections. mAb 13E11 may be a useful tool in studying ECM and more importantly, the putative 
leucine aminopeptidase may function as a biomarker of invasive A. terreus disease. In contrast, 
mAb 19B2 recognized a probable dipeptidyl peptidase V and immunostaining was primarily 
localized within the cytoplasm. These mAbs also have the potential to be used for the 
immunofluorescent detection of A. terreus in bronchoalveolar lavage samples. 
In conclusion, we observed that cAtp antigens were released from vegetative hyphae and 
into CSN in a time-dependent manner. The mAbs developed in this study recognized these 
antigens and the binding was not inhibited by human serum components in spiking experiments. 
Collectively, the data suggest that mAbs developed to cAtp may have potential diagnostic value 
in cases of A. terreus invasive aspergillosis.  Serological detection of A. terreus-specific antigens 
in patient serum would obviate the need to obtain clinical specimens by invasive methods to 
identify the causal agent. Previously, dipeptidyl-peptidase V has been reported as one of the two 
major antigens with the greatest serodiagnostic potential for detecting aspergillosis due to A. 
fumigatus (107, 108, 113, 114). These methodological developments may aid in the development 
of standardized immunoassays for rapid identification of pathogenic species in clinical samples.  
Our goal in these experiments was to develop mAbs to the hemolysin of A. terreus 
(terrelysin) as a potential biomarker of A. terreus infection. In characterizing these mAbs, we 
identified these antigens to be other proteolytic proteins, which appear to be major constituents 
of the cAtp preparation. These proteins may have ‘hemolytic’ activity owing to their general 
proteolytic activity. The mAbs we developed to HEA recognize secreted proteins and have 
potential diagnostic value. Our interest in developing mAbs to the terrelysin to study its 
expression and potential as a biomarker were not achieved and required a different approach. We 
propose to develop terrelysin using recombinant techniques in order to develop highly purified 
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form of the hemolysin. This will also assist in developing standardized reagents for development 
of consistent methodologies. 
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4.1 INTRODUCTION 
 The aegerolysin family (Pfam: PF06355; InterPro: IPR009413) consists of low molecular 
weight, acidic cytolytic proteins from both prokaryotes and eukaryotes. The fungal hemolysins, 
aegerolysin (Agrocybe aegerita), ostreolysin (Pleurotus ostreatus), asp-hemolysin (Aspergillus 
fumigatus) and more recently the hemolysin from the basidiomycete Moniliophthora perniciosa 
have been characterized (1-6). The role of bacterial hemolysins as virulence factors has been 
well established (7, 8) and a similar putative role for the fungal hemolysins has been suggested 
(9, 10). In vitro studies have shown that asp-hemolysin causes lysis of erythrocytes and is 
cytotoxic to macrophages, fibroblasts, leukocytes, and endothelial cells in vitro (11-13). 
Ostreolysin and aegerolysin have been suggested to play an important role in the development of 
fruiting bodies in the basidiomycete fungi (2, 5). 
 As noted previously, rapid identification of fungi at the species level could aid in early 
and improved treatment of fungal infections. Fungal hemolysins have been hypothesized as 
candidates for use as biomarkers for species identification thus aiding in their early detection (10, 
14, 15).  
In characterization of hemolytic preparations from A. terreus culture, we identified the 
presence of multiple proteins. However, we could not detect any mAbs to proteins in the 
expected size range of the specific hemolytic protein, terrelysin. Also, proteomic analysis of the 
hemolytic preparations did not yield any peptides belonging to terrelysin.  
Recently, the genomes of a number of fungi including A. terreus were completed and the 
sequences of aegerolysin-like proteins were reported (16-21). Using homology search, we 
identified the sequence of a putative terrelysin, based on homology to asp-hemolysin (A. 
fumigatus), as a prototype of the aegerolysin family. This chapter describes the development of a 
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recombinant terrelysin by expressing it in Escherichia coli, its purification and the development 
of mAbs to terrelysin. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Culture of A. terreus and cloning of rTerrelysin- Conidia of A. terreus ATCC 1012 (1 
x 10
6
) were inoculated in TSB medium (50 ml). Cultures were grown for 3 days at RT after 
which the mycelium was harvested and washed thoroughly in phosphate buffered-saline (PBS) 
pH 7.4. Total RNA was extracted from mycelium with RNAqueous kit (Ambion Inc. Austin, 
TX). cDNA was synthesized using a High Capacity RNA-to-cDNA Master Mix (Applied 
Biosystems Foster City, CA) according to the manufacturer’s instructions. Terrelysin encoding 
open reading frame was amplified by PCR using cDNA as the template and a PCR SuperMix 
High Fidelity kit (Invitrogen Carlsbad, CA). The following primers were used: forward primer 
(F1) 5’_ATGGTAGGTCTCAGCGCATGGACGACTCTCAATGGGTTTC_3’ and reverse 
primer (R1) 5’_ATGGTAGGTCTCATATCAGGCAGCAGAAATATCAATGAA AACA_3’ 
(BsaI restriction sites are indicated in bold). PCR was performed with initialization at 94ºC for 
30 secs followed by 32 cycles of denaturation at 94ºC for 30 secs, annealing at 68ºC for 30 secs 
and extension at 72ºC for 1 min; with final holding at 68ºC for 1 min. The PCR product was 
ligated into the BsaI-digested pASK-IBA6 vector (IBA-GmbH, Göttingen, Germany), 
transferred into One Shot® TOP 10 chemically competent Escherichia coli cells (Invitrogen). 
Clones were screened by PCR and analyzed on 1.2% agarose gel stained with ethidium bromide 
(200 µg/ml). Bands were observed using a MultiImage
TM
 Light Cabinet (Alpha Innotech 
Corporation, San Leandro, CA). Clones were verified for orientation of the insert by DNA 
sequencing with primers (designated F2 and R2) recommended by IBA.  
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4.2.2 Expression and purification of rTerrelysin- The terrelysin construct was introduced 
into One Shot® BL21 Star
TM 
(DE3) chemically competent E. coli cells (Invitrogen) for protein 
expression. Transformed E. coli were grown in LB medium (50 ml) supplemented with 100 
µg/ml ampicillin overnight at 37ºC. The overnight culture was inoculated into flasks containing 
LB medium (500 ml) supplemented with ampicillin. Cultures were incubated at 37ºC until they 
reached an OD600 of 0.5-0.7. rTerrelysin expression was induced by the addition of 100 µg 
anhydrotetracycline (AHTC) per 500 ml culture, and growth was continued at 30ºC for 3 hrs. E. 
coli were harvested by centrifugation at 12,000 g for 15 mins at 4ºC and the pellet was re-
suspended in 10 ml CelLytic B solution (Sigma, St. Louis, MO). Phenylmethylsulfonyl fluoride 
(PMSF) (100 µl) was added to inhibit endogenous protease activity. Avidin (100 µl, 2 mg/ml) 
was added to sequester endogenous biotin carboxyl carrier protein (BCCP) from E.coli that 
would otherwise bind to the Strep-Tactin column (IBA) and thus interfere with the purification 
of rTerrelysin. The suspension was centrifuged at 12,000 g (4ºC for 15 mins) to remove lysed E. 
coli and cellular debris. The supernatant was applied to an affinity column packed with 10 ml 
Strep-Tactin-sepharose (IBA) and unbound proteins were removed with washing buffer (100 
mM TRIS, 150 mM NaCl, 1 mM EDTA, pH 8) (IBA). rTerrelysin was then eluted with washing 
buffer containing 2.5 mM desthiobiotin, pH 8 (IBA) and the concentration of the purified 
rTerrelysin was determined using a NanoDrop ND1000 Spectrophotometer (Thermo Scientific, 




4.2.3 Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS)- Samples were prepared for MALDI-TOF MS analysis by mixing equal 
volumes of rTerrelysin (500 µg/ml) and α-cyano-4-hydroxycinnamic acid (10 mg/ml). Aliquots 
of 1 µl were air-dried on the gold sample stage (Bio-Rad, Hercules, CA) and MALDI-TOF mass 
spectra were acquired using a Ciphergen PBS-IIc linear TOF mass spectrometer (Bio-Rad, 
Hercules, CA) with a flight path of 0.8 m. Spectra were acquired over the m/z range of 0 to 30 
kDa, with the delayed extraction parameters set to optimally focus the 15 to 20 kDa range. 
Protein calibrants between 1 to 66 kDa were used for external calibration.  
 
4.2.4 Circular Dichroism Spectroscopy- Circular Dichroism (CD) spectra were recorded 
using a JASCO J-810 spectro-polarimeter (JASCO Inc., Easton, MD) under the following 
conditions: Temperature 20ºC; pathlength 0.1 cm; protein concentration 0.2-0.35 mg/ml; 
scanning range between 300-180 nm (Far-UV). For pH effect studies, rTerrelysin was dialyzed 
into the following buffers: pH 3: 20 mM citrate buffer; pH 6-8: 20 mM phosphate buffer; pH 9-
10: 20 mM borate buffer. CD spectra were recorded for rTerrelysin (pH 8) between temperature 
20°C-90°C with a 5°C interval to study the thermal denaturation of rTerrelysin. Baseline 
correction was performed with respective buffers without protein and an average spectrum was 
obtained from 3 scans.  Spectra were fit using CDPro over the range of 260-185 nm.  The fitting 
procedure can be used to predict the tertiary class of the protein assuming it is all α-helix, all β-





4.2.5 SDS-PAGE and protein blot analysis- SDS-PAGE electrophoresis was performed 
using 12% acrylamide separating gel and 4% stacking gels. SDS-PAGE was carried out using 
constant voltage of 100 V for 90 mins and the separated proteins were stained with Imperial
TM
 
protein staining solution (Pierce, Rockford, IL). For protein blots, gels were transferred to a 
nitrocellulose membrane at a constant voltage of 15 V overnight at 4ºC and the membranes 
blocked for 1 hr in 3% bovine serum albumin (BSA) in PBST (PBSTB). After washing with 
PBST, the membrane was incubated for 1 hr with horseradish peroxidase-conjugated Strep-
Tactin diluted 1/100,000 (v/v) (IBA). The blots were subsequently developed with 
tetramethylbenzidine solution (TMB) (KPL Inc., Gaithersburg, MD). 
 
4.2.6 Hemolysis assay- Hemolysis assay was performed by incubating serial dilutions of 
rTerrelysin (5 mg/ml-0.02 mg/ml) in PBS pH 7.4 containing sodium citrate (0.57%). Each 
rTerrelysin dilution (100 µl) was incubated with 100 µl of sheep red blood cells (SRBC) at 
several concentrations ranging from 2 to 5% in PBS pH 7.4 containing 0.57% sodium citrate in a 
96-well microtiter plate. Samples were incubated for 30 mins at RT. SRBC incubated with 
Tween (1%) acted as a positive control and SRBC incubated with PBS acted as a negative 
control. After incubation, plates were centrifuged at 4100 g for 5 mins. The supernatant was 




4.3.1 Sequence alignment of aegerolysin-like proteins- The putative sequence for terrelysin 
was obtained by performing a BLAST search with asp-hemolysin (ASPH_ASPFU) as a search 
query. The search yielded results for homologues present in different Ascomycetes, 
Basidiomycetes, bacteria and plants. A putative uncharacterized protein sequence from 
Aspergillus terreus (Q0CRX8) with 26% identity to Asp-hemolysin was identified. Sequences of 
putative uncharacterized proteins from A. fumigatus, A. terreus, A. flavus, A. clavatus, A. oryzae, 
Penicillium chrysogenum, Agrocybe aegerita, and Pleurotus ostreatus were analyzed using 
Clustal W multiple sequence alignment software (23) (Fig. 4.1). Significant homology was 
observed in the C-terminal region of aegerolysin-like proteins. Terrelysin (Q0CRX8) shares > 
50% identity with putative hemolysins from A. niger (A2RBK6-55%) and A. nidulans (Q5BD27-
69%) and ≥ 30% identity with 13 other aegerolysin-like proteins. Terrelysin Q0CRX8 contained 
a unique sequence DCSRSGLPLLFR at AA 29-40 that was not found in the other aegerolysins.  
 
4.3.2 Cloning and expression of rTerrelysin- Total RNA was isolated from A. terreus and 
reverse transcribed to cDNA. The open reading frame encoding the putative terrelysin (Fig. 4.1) 
was amplified using specific primers F1 and R1, which amplified a 390 bp PCR product that was 
cloned into the pASK-IBA6 vector (Fig. 4.2). The open reading frame did not contain the 
sequence for the peptide AA29-40 found in Q0CRX8, which instead was replace by a glutamic 





Fig 4.1.  Sequence alignment of putative aegerolysin family proteins produced by various fungi. Alignment was 
performed using Clustal W. Proteins were identified by their database accession numbers. Abbreviations of 
organisms from which the proteins were identified. PENCH: Penicillium chrysogenum, ASPOR: Aspergillus 
oryzae, ASPFL: Aspergillus flavus, ASPFU: Aspergillus fumigatus, ASPCL: Aspergillus clavatus, ASPNG: 
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Aspergillus niger, AGRAE: Agrocybe aegerita, PLEOS: Pleurotus ostreatus. The full-length sequence of 
terrelysin identified by translation of the cDNA sequence is identified as cDNA, while the recombinant sequence 
without the Strep-tag II is identified as rTerrelysin. The % identities and % similarities were reported from 
BLAST results on EBI website. ‘*’ Fully conserved residues, ‘:’ strongly conserved residues, ‘.’ weakly conserved 
residues. N.A. is defined as “not determined” using the BLAST tool on EBI website with terrelysin (Q0CRX8) as 
a query. The query did not yield results for identities and similarities for ostreolysin (Q56QW9). Sequence 
analysis was performed on August 12, 2009. 
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Using the primers F2 and R2 the ligation of the insert in the pASK-IBA6 vector was 
verified. The terrelysin insert was not present in unligated pASK-IBA vector (Lane 2) but was 
present after ligation into the vector (Lane 3) as observed by an approximately 390bp difference 
in bands on the gel. After transferring the plasmid into competent E. coli by heat-shock 
transformation, positive clones were selected on the basis of ampicillin resistance and the correct 
orientation of the insert was confirmed by sequencing primers F2 and R2. Clones expressing the 
terrelysin sequence in the proper reading frame were identified and chosen for further study. The 
presence of terrelysin cDNA was demonstrated in the TOP 10 cloning strain (Lane 5) and the 
BL21 (DE3) expression strain (Lane 6) of E. coli, but not in the original E. coli DH5α strain 










4.3.3 Characterization of rTerrelysin- The pASK-IBA6 vector is designed for expression of 
the recombinant protein into the periplasmic space through a signal peptide OmpA inserted at the 
N-terminal of the recombinant protein. The signal is cleaved by endogenous signal peptidase 
during the protein translocation resulting in the release of the protein into the periplasmic space. 
Immediately downstream of the OmpA signal the pASK-IBA6 vector contains a Strep-tag II and 
Factor Xa recognition sequence at the N-terminus that is a part of the rTerrelysin polypeptide.   
Protein preparations from uninduced E. coli, AHTC induced E. coli, and Strep-Tactin 
column purified rTerrelysin were analyzed by SDS-PAGE (Fig. 4.4a). An ~ 17 kDa band 
representing rTerrelysin was observed only in induced cultures (Lane 3) and the purified fraction 
(Lane 4), but was absent in the uninduced cultures (Lane 2).  
Protein blots were performed and rTerrelysin was identified using HRP-conjugated Strep-
Tactin and TMB as a substrate (Fig. 4.4b). A band corresponding to rTerrelysin was present in 
AHTC induced cultures (Lane 5) and in the Step-Tactin column-purified fraction (Lane 6), but 
absent in uninduced (Lane 4) or induced E. coli cultures without the insert (Lane 3). The bands 
observed in Lanes 4 and 5 at ~ 17 kDa just above the rTerrelysin band could possibly be BCCP 
from E. coli. This band is absent in purified preparation (Lane 6) suggesting the removal of 
BCCP after addition of avidin prior to purification on the Strep-Tactin column.  
The mass of rTerrelysin was determined using MALDI-TOF MS (Fig. 4.5). The single 
charged [M+H]
+
 ion of rTerrelysin was observed at m/z 16428, in good agreement with SDS-
PAGE results (Fig. 4.4). The peak observed at m/z 8197 represents the doubly charged [M+2H]
2+
 





Fig 4.3.  Agarose gel electrophoresis. Lane 1: DNA ladder, Lanes 2, 4: pASK-IBA6 vector with no insert (PCR 
products of primers F2 and R2), Lanes 3, 5, 6: pASK-IBA6 vector with terrelysin gene insert (PCR products of 






Fig 4.4a. SDS-PAGE for terrelysin. Lane 1: Molecular weight marker, Lane 2: Uninduced pASK-IBA6 vector 
(with terrelysin insert), Lane 3: Induced pASK-IBA6 vector (with terrelysin insert), Lane 4: Recombinant 




Fig 4.4b. Protein blot for rTerrelysin. Lane 1: Molecular weight marker, Lane 2: Uninduced pASK-IBA6 vector 
(no insert), Lane 3: Induced pASK-IBA6 vector (no insert), Lane 4: Uninduced pASK-IBA6 vector (with 
terrelysin insert), Lane 5: Induced pASK-IBA6 vector (with terrelysin insert), Lane 6: Recombinant terrelysin 




Fig 4.5.  MALDI-TOF MS of rTerrelysin. [M+H]
+
: 16428.4 Da. [M+2H]
2+
: 8196.7 Da. 
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4.3.4 Secondary structure of rTerrelysin- The secondary structure of rTerrelysin was 
determined using far-UV (185-240) CD spectroscopy analysis (Fig. 4.6). The lowest ellipticity at 
216 nm combined with the highest ellipticity at 195 nm, identified rTerrelysin as a 
predominantly β-sheet protein (Fig. 4.6a). This result was further supported by fitting the data 
with the prediction that the protein was completely in the β-sheet conformation. The effect of 
different pH (3-10) on rTerrelysin unfolding was studied. The optimum β-sheet conformation 
was observed at pH 8. With decreasing pH, a decrease in β-sheet conformation population was 
observed, with the loss of almost all of the β-sheet conformation at pH 3 (Fig. 4.6b). A similar 
effect was observed with the change in pH from 8-10 (data not shown). With the increase in 
alkalinity a gradual decrease in β-sheet conformation was observed.  
 Thermal denaturation studies with rTerrelysin and its effect on its secondary structure 
was studied using CD spectroscopy with monitoring the spectra of rTerrelysin from 20°C-90°C 
with a 5°C interval. The spectra revealed a gradual shift from a predominantly β-sheet 
conformation to a α-helical structure with the increasing temperature (Fig. 4.6c). Spectrum 
measurement in the far UV range identified three different states of secondary structure 
conformation for rTerrelysin. Between 20°C-65°C, the CD spectrum revealed predominantly β-
sheet structure. Between 65°C-75°C, the spectrum showed a possible intermediate structure with 




4.3.5 Hemolysis assay- The rTerrelysin preparation showed hemolytic activity when tested on 
agar plates containing SRBC with a zone of clearance around the site of inoculation (data not 
shown). Dose-dependent hemolysis was analyzed by incubating dilutions of rTerrelysin with 
varying concentrations of SRBC. Hemolysis was measured spectrophotometrically as release of 
hemoglobin at 540 nm (Fig. 4.7). Hemolysis, with a steep dose-response curve was observed at 
relatively high concentrations of rTerrelysin higher than 313 µg/ml.  
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Fig 4.6. Secondary structure analysis of rTerrelysin. a) CD analysis of rTerrelysin. Negative signal at 216 nm 
and a positive signal of similar magnitude at 195 nm identify the protein as a predominantly β-sheet protein.  
b) rTerrelysin was dialyzed into various buffers of differing pH.  Optimum β-sheet conformation was observed at 
pH 8 with a reduction in β-sheet conformation with decreasing pH. A disordered secondary structure is observed 
at pH 3. c) Thermal denaturation of rTerrelysin was studied between temperatures 20°C-90°C. rTerrelysin 
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retained β-sheet structure up to 65°C and beyond that the structure included α-helix elements. Above 75°C, the 




Fig 4.7.  Hemolysis assay. Hemolysis was observed at high concentrations of purified rTerrelysin. Increased 




 Hemolysins are proteins that lyse red blood cells as well as various other eukaryotic cells. 
Here we report the cloning, expression and purification of a recombinant fusion protein of a 
putative hemolysin produced by A. terreus called terrelysin. Terrelysin belongs to the 
aegerolysin family of proteins that consists of cytolysins produced by other filamentous fungi, 
bacteria, and plants (9). A search using the terrelysin sequence as a template in the NCBI-
BLAST2 – Protein Database Query yielded sequence similarities to 40 other proteins from 
different fungi, bacteria and certain members of kingdom Animalia such as Schistosoma 
japonicum and Ciona intestinalis. Terrelysin is a 141 AA protein with a predominantly β-sheet 
structure and a predicted molecular weight of 15,805 Da and a pI of 5.23. 
 Recombinant terrelysin was expressed as a Strep-tag II fusion protein in the pASK-IBA6 
vector. An apparent intron sequence (DCSRSGLPLLFR) found in the genomic sequence 
Q0CRX8 was not found in the cDNA transcribed from A. terreus mRNA. In addition, we 
truncated the recombinant protein at AA 130 to better correspond with other aegerolysins. The 
recombinant also contained the linker, Strep-tag II and Factor Xa recognition sequences 
(ASWSHPQFEKIEGR) at the N-terminus giving the fusion protein a predicted MW of 16,290 
Da and pI of 4.91.  
The benefit of using the Strep-tag II system rather than other, more common systems 
such as histidine tag (His6), is that it is less likely to interfere with protein folding or function 
(24-28). For example, asp-hemolysin has been cloned and expressed as a Maltose Binding 
Protein (MBP) fusion construct, however, this protein was not functionally active (3, 4). Other 
proteins from the aegerolysin family (Cbm 17.1 and Cbm 17.2 produced by Clostridium 
bifermentans) were produced as His6-tag fusion proteins (29) that failed to be hemolytic. 
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Similarly, His6-tagged PA0122 protein from Pseudomonas aeruginosa was also successfully 
expressed in E. coli but found to be non-hemolytic (30). His6-tag constructs of terrelysin were 
also made in our lab and we did not observe any hemolytic activity with them. With the MBP-
tagged protein, the large size of MBP (42.7 kDa) may affect the conformation and function of 
asp-hemolysin (14.2 kDa) (4), but to date recombinant hemolysins have been functionally 
inactive. 
In preliminary experiments, we observed the rTerrelysin Strep-tag II fusion protein 
preparation to have hemolytic activity against SRBC. However, given the rather steep dose 
response and the significant doses required, the possibility of surfactants or detergents being 
present in rTerrelysin preparation could not be ruled out. The CelLytic B solution used for lysing 
E. coli cells contains a proprietary formulation with detergents, which could not be completely 
removed by dialysis. Recent research has identified the requirement of a co-factor for the 
functional activity of pleurotolysin (31, 32). Whether a co-factor is required for terrelysin 
activity will require further work but this helps to further explain the lack of functional activity 
of recombinant hemolysins. 
 Sequence alignment of multiple aegerolysin family proteins demonstrated that most 
conserved residues were present in the C-terminal region of the protein sequences.  The 
hemolysins of A. oryzae and A. flavus in the genomic database were observed to share the exact 
same sequence. These two species belong to the Aspergillus section Flavi, and are 
phylogenetically closely related (20, 33, 34). Interestingly, it was also observed that members of 
the aegerolysin family share some structural homology with a family of proteins that contain an 
E-set domain (Conserved Domain Database: cl09101) for sugar utilizing enzymes (35, 36). 
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Although aegerolysins are typically characterized as hemolysins, they may have other enzymatic 
functions not yet identified.  
 Differences in mass of fungal hemolysins have been reported (1, 2, 37-39). Aegerolysin 
family proteins are typically low molecular weight (~14-17 kDa) proteins. Our experimentally 
determined rTerrelysin mass is in good agreement with those of other members of the 
aegerolysin family (2, 4, 29, 30). The secondary structure is very important for functionality of 
native hemolysins since they undergo conformational changes once inserted into the target 
membrane, to induce pore formation (40). We expressed rTerrelysin in the periplasmic space of 
E. coli to allow for proper folding of the protein.  
The secondary structure of aegerolysin family proteins has been predicted to be 
predominantly β-sheet (41, 42). The secondary structures of nigerlysin and ostreolysin have been 
reported (38, 41). While nigerlysin was reported as α-helical structure, ostreolysin was identified 
as a β-sheet protein. β-sheet structures have also been identified in bacterial hemolysins such as 
alpha toxin of Staphylococcus aureus and perfringolysin-O of Clostridium perfringens (43, 44). 
We have identified rTerrelysin as a predominantly β-sheet protein and it may be similar in 
function to some of the bacterial hemolysins that play a role in pathogenesis.  
 Our findings on terrelysin unfolding as a result of pH changes confirm the observations 
of Berne et al. on ostreolysin (41). These authors suggested that ostreolysin might exist in 
conformationally distinct states as a function of pH. The authors identified the optimum β-sheet 
conformation at ~ pH 8, an observation that has been confirmed for several hemolysins (45, 46). 
Berne et al. also reported that as the pH is shifted to the acidic or alkaline range, the 
conformation of the protein changes.  The disordered conformation of rTerrelysin at pH 3 may 
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provide the protein flexibility that it lacked in the β-sheet conformation. This flexibility may 
increase the formation of oligomers and in pore formation. 
A. terreus is a thermotolerant organism capable of growing at elevated temperatures of up 
to 50º C. Our thermal denaturation studies on the secondary structure of rTerrelysin indicate that 
the β-sheet conformation of the recombinant protein is stable up to 65°C. Presence of a 
thermostable protein may provide the fungus an advantage in colonizing in elevated soil 
temperatures or within human body.  
The aegerolysin family of proteins is an interesting new group of proteins that may have 
multiple functions. In basidiomycetes (mushrooms), they have been found to accelerate fruiting 
body formation (2, 47) and may be critical during germination of spores of filamentous fungi. 
Their role in pathogenesis appears to be related to their cytolytic activities (12, 13, 48). 
Interestingly, ostreolysin and other aegerolysins may bind microhetereogeneic domains within 
the membrane that are rich in cholesterol (49). Some have also characterized the binding of asp-
hemolysin to low density lipoproteins (50-52). Preliminary studies have suggested the possibility 
of the use of fungal hemolysins as diagnostic markers (10, 53).  
Future studies will be aimed at generating monoclonal antibodies to rTerrelysin and 
developing inhibition ELISA methods using rTerrelysin as reference standard to quantify 
terrelysin in human serum samples or environmental samples. These experiments will help to 
further understand the biological significance of terrelysin, its expression, localization and 
potential use as a biomarker for exposure to A. terreus. 
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Development of monoclonal antibodies to recombinant terrelysin 
and characterization of terrelysin expression in Aspergillus terreus 
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5.1 INTRODUCTION 
Hemolysins have been suggested to play a key role in pathogenesis by lysing host cell 
membranes, which assists in causing infection (1-3). However, less is understood about the 
biological relevance of these hemolytic proteins in fungi. Fungal hemolysins have been studied 
for a few decades for their role as virulence factors (4-7), their lipoprotein-binding properties (8, 
9) and utility as unique markers of micro-domains on eukaryotic cell membranes (10, 11). Plants, 
animals and humans are opportunistic hosts of the fungus and these hemolytic proteins may have 
distinct functions in fungal biology in nature. Their hemolytic activity and other cytotoxic 
properties associated with host factors may only be coincidental. Some studies have earlier 
reported involvement of these hemolysins in the morphology and development of fungi 
especially mushrooms (12, 13). However, limited information is currently available on 
expression and localization of these hemolysins in filamentous fungi, which may be essential in 
ascertaining a role for these proteins in fungal biology. 
In our previous work we attempted to develop mAbs to fungal hemolysins using partially 
purified hemolytic preparations. This lead to identification of multiple proteins in the preparation 
and we identified some of these proteins to be proteolytic enzymes. In our effort to study the 
specific hemolysin of A. terreus, terrelysin, we cloned the gene for terrelysin and expressed the 
protein in E. coli. The recombinant rTerrelysin was purified and used in production of 
monoclonal antibodies (mAbs) for characterization of expression of terrelysin by A. terreus and 
development of immunoassays for detection of terrelysin as a surrogate biomarker for exposure 
to A. terreus. 
In this report we describe the generation of monoclonal antibodies (mAbs) to terrelysin, 
their purification and characterization of kinetics of native terrelysin expression by A. terreus. 
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We will also use these tools to study the localization of terrelysin within the fungal hyphae and 
conidia. This will help in suggesting putative functions for these proteins in fungi.   
                          
5.2 METHODS AND MATERIALS 
5.2.1 Production of monoclonal antibodies against rTerrelysin- Three 8-10 week old 
BALB/c mice (The Jackson Laboratory, Bar Harbor, ME) were housed in the animal facility at 
the National Institute for Occupational Safety and Health (NIOSH), Morgantown, WV. The 
facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International (AAALAC) and animals were free of viral pathogens, parasites, mycoplasma, 
and Helicobacter spp. Animals were housed together in a HEPA-filtered ventilated 
polycarbonate cages on autoclaved hardwood Beta-chip bedding with cotton fiber nesting 
material. The animals were provided with Teklad 7913 rodent chow (Harlan Laboratories, 
Madison, WI) and autoclaved tap water ad libitum. All animal procedures and immunizations 
were reviewed and approved by the NIOSH Animal Care and Use Committee (ACUC). 
Prior to immunization, blood samples were collected from the tail vein and the serum was 
stored at -20°C. Each animal was immunized 3 times, every other week with 25 µg of purified 
rTerrelysin emulsified (50% v/v) in TiterMax® (TiterMax USA, Norcross, GA) adjuvant. The 
mice were monitored for adverse health effects post immunizations. Between immunizations, 
serum was collected from the tail vein to monitor for rTerrelysin-specific IgG antibody response.  
Following the development of sufficient IgG titers, the animals were euthanized by CO2 
asphyxiation. The spleen was aseptically removed from each mouse and single cell suspensions 
of the splenocytes produced. Fusion of splenocytes with SP2/0-Ag 14 myeloma cells (ATCC# 
CRL-1581) was performed as previously described (14). Hybridomas were selected by growing 
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cells in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, Rockville, MD) 
supplemented with 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.292 
mg/ml L-glutamine, 100 mM sodium hypoxanthine, 16 mM thymidine, 10% fetal calf serum 
(FCS) (HyClone, Logan, UT), and 100 U/ml IL-6 (Boerhinger, Mannheim, Germany). DMEM 
was also supplemented with azaserine for selective propagation of hybridomas. After 10-14 days 
of growth, medium from individual wells with growth of hybridoma cells was replenished with 
fresh DMEM medium. The supernatants from individual hybridoma colonies were tested in 
ELISA to detect presence of antibodies specific to rTerrelysin.  
Supernatants of individual clones were tested twice to confirm reactivity of antibodies. 
Hybridomas from each positive well was further cloned, twice by limiting dilution analysis and 
single positive clones were screened and selected for production of large quantities of mAbs. 
Positive clones were frozen in 10% dimethyl sulfonic acid (DMSO) and stored at -80°C for 2 
weeks and later transferred to liquid nitrogen facility for long-term storage. 
 
5.2.2 Production, isotyping and quantification of rTerrelysin mAbs- All rTerrelysin mAbs 
were concentrated and partially purified by ammonium sulfate precipitation as described 
previously (15). Briefly, mAb supernatant collected from individual hybridomas was centrifuged 
at 20,000 g for 30 min at 4°C. The supernatant was collected and saturated ammonium sulfate 
was slowly added to the supernatant to 45% (v/v) and incubated for 8-10 hrs at 4°C. The tubes 
were centrifuged for 45 mins at 20,000 g at 4°C and the precipitate was collected and 
resuspended in PBS, pH 7.4. Concentration of purified antibodies and their isotype were 
determined using methods described earlier. 
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5.2.3 Fungal cultures and extracts- For time point assay, fungal cultures were grown by 
inoculating 50 ml minimal medium containing glucose, nitric salts and trace elements with 2.5 x 
10
7
 A. terreus viable conidia. Viability was determined using LIVE/DEAD® BacLight
TM
 
Viability kit (Molecular Probes, Inc., Eugene, OR) as described previously (16). Following 
inoculation, flasks were incubated at either RT or at 37°C depending on the specific 
experimental design. A. terreus cultures were grown for 12 days with an individual flask 
representing a 24 hr time point were collected each day. A. terreus culture and mycelial pellets 
were collected in 50 ml tubes and centrifuged at 4100 g for 10 mins. The culture supernatant 
(CSN) and mycelial pellets were collected and stored at -80°C and the lyophilized CSN residue 
was resuspended in PBS, and mycelial pellets were processed using a mortar and pestle with 
PBS containing Complete Mini Protease Inhibitor Cocktail (Roche Diagnostics, Indianapolis, 
IN). Mycelial slurry was then collected into 15 ml polypropylene tubes and incubated at 4°C 
overnight on a shaker to facilitate the release of intracellular proteins into the lysis solution. The 
next day, mycelial extracts (ME) were centrifuged at 4100 g for 10 mins and the supernatant 
collected and stored at -20°C until analysis. 
 For cross-reactivity studies, ME were prepared from 29 different fungal species including 
12 different Aspergillus species using the same method (Table 1.) Fungi were grown till 
mycelial pellets had formed (3-4) days. Protein concentrations of CSN and ME were estimated 




5.2.4 ELISA methods- Screening mAbs. Hybridomas producing anti-rTerrelysin mAbs were 
identified by indirect ELISA. In brief, 96-well Immuno MaxiSorp microplates (Nunc, Rochester, 
NY) were coated with rTerrelysin (1 µg/ml) in 0.05 M carbonate coating buffer pH 9.6 (CCB), 
and blocked with phosphate buffered saline (PBS) containing 0.5% Tween-20 and 5% nonfat dry 
milk (PBSTM) for 1 hr. CSN from each hybridoma was incubated in duplicate wells for 1 hr at 
37°C, washed with PBS containing 0.5% Tween-20 (PBST), and detected using alkaline 
phosphatase conjugated goat-anti mouse IgG antibody (H+L) (Promega, Madison, WI) diluted 
1:5000 in PBSTM for 1 hr at 37°C. The wells were then washed in PBST and developed for 30 
min using 4-paranitrophenyl phosphate substrate (Sigma). Reactivity was determined by 
measuring the optical density (OD) at 405 nm. TO compare the reactivity of identified mAbs, 
each mAb was purified and used at a concentration of 1 µg/ml and assayed with various dilutions 
of rTerrelysin bound to the assay plate. The plates were washed 3 times between individual steps 
of incubation with PBST. 
Inhibition ELISA for analysis of kinetics of terrelysin expression. An inhibition ELISA 
was performed over a period of 2 days. On day 1, the ‘assay plate’ was coated with 0.1 µg/ml of 
rTerrelysin and a second plate ‘inhibition plate’ was blocked overnight with PBSTM to prevent 
protein binding. On day 2, both plates were washed with PBST and the ‘assay plate’ was blocked 
with PBSTM at RT for 2 hrs. In the inhibition plate, serial dilutions of ME and CSN samples  
(protein concentration range 5 mg/ml-0.078 mg/ml) and serially diluted rTerrelysin standard time 
points (days 1-12). Standards were set up by serial dilution of rTerrelysin (protein concentration 
range 1 mg/ml-78 µg/ml) were incubated with 40 ng/ml of anti-terrelysin mAb 10G4. Negative 
control wells were incubated with PBS and positive control wells were incubated with mAb 
10G4 alone. The inhibition plate was incubated on a shaker at RT for 1 hr at 200 rpm and for 30 
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min without shaking. Next, the assay plates were washed and incubated with 100 µl of reaction 
mixture from the inhibition plate at 37°C for 1 hr. Plates were washed and incubated with 
alkaline phosphatase conjugated goat anti-mouse IgG antibody (H+L) diluted 1:5000 in PBSTM 
for 1 hr at 37°C. Plates were washed and developed using 4-paranitrophenyl phosphate substrate. 
Reactivity was measured at OD at 405 nm and terrelysin concentrations were determined for 
each sample by comparing to the standard curve using regression analysis.  
 
5.2.5 Western blot analysis of rTerrelysin and fungal ME- Reactivity to rTerrelysin and 
native terrelysin. Pooled polyclonal sera collected each immunized mouse was tested using 
Western blot with rTerrelysin and A. terreus ME. A. terreus ME was collected from 3 days old 
cultures grown in TSB for 72 hrs at RT. rTerrelysin (50 ng) and A. terreus ME (25 µg) were 
separated using a 12% acrylamide gel and transferred to a nitrocellulose membrane. The 
membrane was blocked for 1 hr in PBST containing 3% bovine serum albumin (BSA) (PBSTB) 
and incubated with anti-rTerrelysin pooled polyclonal sera (1/2000 v/v) in PBSTB for 1 hr at RT. 
The membrane was washed 3 times with PBST and then incubated with alkaline phosphatase 
conjugated goat anti-mouse IgG. The membrane was washed again and immunoreactive proteins 
were detected using the chromogenic substrate NBT/BCIP (Promega, Madison, WI).  
Western blot analysis was performed for screening individual mAbs reactivity to 
rTerrelysin, native terrelysin (A. terreus CSN and ME extracts), and for cross-reactivity analysis. 
rTerrelysin (500 ng/ml) and ME (2.5 mg/ml) collected from day 4 culture of A. terreus were 
individually separated by performing SDS-PAGE on a 12% polyacrylamide gel. For cross-
reactivity testing, ME (2.5 mg/ml) from 29 different fungal species were separated on 12% 
polyacrylamide gels. Proteins were transferred overnight to nitrocellulose membranes (0.22 µm, 
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BioRad) and the membranes were blocked using Tris-buffered saline (TBS) containing 0.1% 
Tween-20 (TBST) and 3% bovine serum albumin (blocking buffer). Membranes were washed 
with TBST and transferred to a BIO-RAD Multi Screen apparatus (BioRad, Hercules, CA). 
Individual lanes were incubated with 1 µg/ml of mAbs diluted in blocking buffer and incubated 
on a rocker for 1 hr. Membranes were washed 3X with TBST, and incubated with alkaline 
phosphatase-conjugated goat anti-mouse IgG antibody (H+L) diluted 1:5000 in blocking buffer 
for 1 hr on a rocker. Membranes were then washed with TBST and developed for 15-20 mins 
using 1-Step NBT/BCIP (Promega, Madison, WI) substrate solution. The reaction was stopped 
by washing the membranes with distilled water. 
  
5.2.6 Epitope mapping- Epitope mapping was performed using synthetic peptides synthesized 
by Sigma Genosys (JPT Peptide Technologies GmbH, Berlin, Germany) using methods 
previously described (17). For peptide scans, 68 peptides spanning the entire rTerrelysin 
(including the Strep-tag II sequence) were synthesized as linear decapeptides overlapping by 2 
amino acids. Peptides were covalently bound to a Whatman 50 cellulose support (PepSpots 
membrane) at the C-terminus and N-terminus of peptides was acetylated for higher stability. The 
membranes were processed for epitope mapping per the manufacturer’s instructions.  
 In brief, the PepSpots membrane was rinsed in methanol for 5 mins, washed 3X with 
TBS for 10 mins, blocked overnight at 4°C on a shaker with TBS containing 3% BSA. The 
membrane was incubated with 5 µg/ml of rTerrelysin mAbs for 3 hrs at RT on a shaker. The 
mAb 9B4, an IgG1 isotype, which recognizes a Stachybotrys chartarum conidial surface protein 
served as a negative control. The membrane was washed in TBST 3X for 5 min each and then 
incubated with goat anti-mouse IgG horseradish peroxidase (HRP) conjugated antibody 
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(Promega, Madison, WI) diluted 1:50,000 in blocking buffer for 1 hr at RT on shaker. The 
membrane was washed thoroughly in TBST 3X for 5 mins each and developed with ECL 
Western blotting substrate (Promega) as per manufacturer’s instructions. After a brief incubation, 
excess substrate was discarded and the membrane was exposed to CL-XPosure
TM
 clear blue X-
Ray film (Thermo Scientific, Rockford, IL) and developed using a SRX-101A tabletop processor 
(Konica Minolta, Ramsey, New Jersey). For regeneration, the PepSpots membrane was washed 
twice with water for 10 mins each and then incubated with regeneration buffer I (62.5 mM TRIS 
containing 2% SDS, pH 6.7; 100 mM 2-mercaptoethanol) at 50°C using four 30 mins 
incubations. The membranes were washed 3X for 20 mins with PBS (10X), 3X with TBST for 
20 mins and 3X with TBS for 10 mins at RT. The membrane was analyzed to ensure efficient 
removal of bound primary and secondary antibodies prior to analysis of new mAbs. 
 
5.2.7 Microscopic examination of A. terreus morphological changes- In order to correlate 
the expression of terrelysin to associated growth changes in A. terreus, we cultivated A. terreus 
in 24-well plates containing 2 ml of minimal medium. Wells were incubated with 1 x 10
6
 viable 
A. terreus conidia and incubated on a shaker at either RT or 37°C. Growth of A. terreus was 
monitored at various time points using Olympus IX70 microscope (Olympus Corporation, 
Tokyo, Japan) and images were captured using a QImaging Retiga 2000R Fast camera 
(QImaging, Surrey, Canada) and processed using the SimplePCI6 software (Hamamatsu 
Corporation, Sewickley, PA).  
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5.2.8 Confocal Scanning Laser Microscopy (CSLM) analysis for localization of native 
terrelysin in A. terreus- Immunolocalization of terrelysin was studied using a slight 
modification of previously described methods (18, 19). Briefly, A. terreus FGSC 1156 cultures 
were grown on alcohol-sterilized cover slips in 6-well tissue culture plates that contained 
minimal medium. Cultures were incubated at 37°C under static conditions for 24 hrs. Cover slips 
were fixed with 8% formalin buffered saline containing 50 mM PIPES (pH 6.7), 25 mM EGTA, 
1% dimethyl sulfoxide (DMSO) and 5 mM MgSO4 for 1 hr at RT and the cover slips were then 
rinsed with MTSB (50 mM PIPES (pH 6.7), 5 mM EGTA and 5 mM MgSO4). Cell wall 
digestion was carried out for 1 hr at RT with an enzyme solution containing 2.5% Driselase® 
(Sigma, St. Louis, MO), 1% lysozyme from chicken egg white (Sigma) and 2 mM EGTA. Cells 
were rinsed with H2O and then treated with 0.1% Triton X-100 in TBS pH 7.4 for 10 mins. Cells 
were then rinsed in MTSB and TBS once each. Cells were blocked with 3% bovine serum 
albumin in TBS (TBSB) overnight at 4°C with gentle shaking. Next, the cover slips were 
incubated with mAb 15B5 at 3 µg/ml in TBSB for 3 hrs with gentle shaking. mAb 9B4 (S. 
chartarum conidial surface protein) served as a negative control (20). mAb 13E11 described 
earlier in chapter 3, and reacts with hyphal exoantigen leucine aminopeptidase from A. terreus 
served as a positive control. Cells were washed thoroughly in TBS containing 0.05% Tween 20 
(TBST) and stained with AlexaFluor® 594 conjugated goat anti-mouse IgG (H+L) (Molecular 
Probes Inc., Eugene, OR) diluted 1:50 in TBSB for 1 hr at RT. Cells were washed in TBST and 
cover slips were placed on clean slides with ProLong® Antifade Reagent with DAPI (Molecular 
Probes Inc.). Cells were observed with a Zeiss LSM-510 Meta Confocal Microscope System 
(Axioplan 2 Stand) (Carl Zeiss, Thornwood, NY) and the images were acquired with Zeiss 
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software version 3.2 (Carl Zeiss). All settings on the confocal laser microscope remained 
constant throughout the analysis. 
 
5.3 RESULTS 
5.3.1 Isotyping and sensitivity screening of rTerrelysin mAbs- Mice immunized with 
rTerrelysin developed detectable specific IgG after the first immunization that increased with 
subsequent immunizations. Thirty-two hybridomas recognized rTerrelysin during the initial 
screening. Sixteen clones survived the multiple cloning steps and were further analyzed in 
screening, cross-reactivity, and immunolocalization experiments. Nine clones (2G4, 3B2, 6D2, 
7D8, 13G10, 15B5, 16C7, 9F4, 19E3) produced IgG1 isotype mAbs, 4 (3B7, 10G4, 15C5, 15E4) 
produced IgG2a isotype mAbs and 3 (6E4, 10G7, 2D3) produced IgG2b isotype mAbs. The mAbs 
exhibited variable reactivity to immobilized rTerrelysin in ELISA (Fig. 5.1). mAbs 2G4, 9F4, 
19E3, 6E4 and 15E4 showed least reactivity (≤ 0.25 OD405 value) to rTerrelysin (data not 
shown). mAbs 3B2, 6D2, 7D8 and 16C7 showed moderate reactivity (Fig. 5.1a), while mAbs 








Fig 5.1. Reactivity of mAbs to rTerrelysin. Moderate reactivity is defined as ≤ 1.0 (OD405 value) in assay with 1 
µg/ml of mAb concentration. High reactivity is defined as ≥ 1.0 (OD405 value) in assay with 1 µg/ml of mAb 
concentration. 
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5.3.2 Western blot reactivity of pooled sera and mAbs to rTerrelysin and native 
terrelysin- Pooled sera from mice immunized with rTerrelysin was used to confirm the presence 
of immunoreactive terrelysin in extracts from the mycelia of A. terreus (Fig. 5.2). Western blot 
analysis revealed reactivity to denatured rTerrelysin (16.5 kDa) for 11 of the 16 mAbs (Fig. 
5.3a). The higher molecular weight bands observed in the lanes with purified rTerrelysin are 
likely to be aggregates formed during the storage of the protein at -20°C. For native terrelysin, 4 
of the 11 mAbs (3B2, 6D2, 16C7 and 2D3) did not show any reactivity with A. terreus ME (Fig. 
5.3b). Seven mAbs (7D8, 13G10, 15B5, 3B7, 10G4, 15C5, and 10G7) reacted to a putative 




Fig 5.2. Western blot analysis with pooled sera. Lane 1: Molecular weight marker, Lane 2: rTerrelysin and Lane 
3: mycelial extract from 72 hr old culture of A. terreus. 
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5.3.3 Cross-reactivity and strain variations- Five strains of A. terreus including the 
pathogenic strain FGSC 1156 and the commonly used environmental strain ATCC 1012 were 
analyzed with each mAb by Western blot. All mAbs, except 7D8, exhibited reactivity to a 
protein of the same molecular weight in ME derived from all strains (Table 5.1). Interestingly, 
the mAb 7D8 reacted to ME from 3 strains but 2 strains (NIOSH 17-30-31 and NIOSH 35-08-
06) did not react. 
ME from 11 other Aspergillus species including the pathogens A. fumigatus, A. flavus, A. 
nidulans and A. niger were also tested. mAb 15C5 showed maximum cross-reactivity among the 
mAbs tested, exhibiting cross-reactivity to ME from 6 different fungi, including A. nidulans and 
A. parasiticus. mAb 10G7 did not cross-react with any tested Aspergillus species tested here, but 
it did react to ME from E. rostratum, P. variotii and T. harzianum. mAb 3B7 cross-reacted to 
ME from C. cladosporioides. No cross-reactivity was observed with any mAbs against ME from 
4 different Penicillium species. 4 mAbs (7D8, 13G10, 15B5 and 10G4) did cross-react with any 





Fig. 5.3a. Western blot reactivity of rTerrelysin-mAbs with rTerrelysin. Lane 1: Molecular weight marker, 2: 
mAb 2G4, 3: mAb 3B2, 4: 6D2, 5: mAb 7D8, 6: mAb 13G10, 7: mAb 15B5, 8: mAb 16C7, 9: mAb 9F4, 10: mAb 
19E3, 11: mAb 3B7, 12: mAb 10G4, 13: mAb 15C5, 14: mAb 15E4, 15: mAb 6E4, 16: mAb 10G7, 17: mAb 2D3. 




Fig. 5.3b. Western blot analysis of A. terreus mycelial extract with terrelysin mAbs. Lane 1: Molecular weight 
marker, 2: mAb 2G4, 3: mAb 3B2, 4: 6D2, 5: mAb 7D8, 6: mAb 13G10, 7: mAb 15B5, 8: mAb 16C7, 9: mAb 
9F4, 10: mAb 19E3, 11: mAb 3B7, 12: mAb 10G4, 13: mAb 15C5, 14: mAb 15E4, 15: mAb 6E4, 16: mAb 10G7, 
17: mAb 2D3. Positive reactivity is identified by presence of an immunoreactive band at ~ 17 kDa. 
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FUNGI 7D8 13G10 15B5 3B7 10G4 15C5 10G7 
As. terreus FGSC 1156 + + + + + + + 
A. terreus ATCC 1012 + + + + + + + 
A. terreus NIOSH 17-30-31 - + + + + + + 
A. terreus NIOSH 35-08-05 + + + + + + + 
A. terreus NIOSH 35-08-06 - + + + + + + 
A. candidus NIOSH 17-28-24 - - - - - - - 
A. chevalieri NRRL 78 - - - - - - - 
A. clavatus NIOSH 6-22-78 - - - - - - - 
A. flavus NIOSH 15-41-07 - - - - - - - 
A. fumigatus FGSC A1100 - - - - - - - 
A. nidulans NIOSH 15-22-08 - - - - - + - 
A. niger FGSC A1143 - - - - - - - 
A. parasiticus ATCC 26690 - - - - - + - 
A. penicilloides ATCC 16910 - - - - - - - 
A. repens NRRL 13 - - - - - - - 
A. ustus NRRL 275 - - - - - - - 
Ac. strictum ATCC 46646 - - - - - - - 
Al. alternata ATCC 11612 - - - - - + - 
Ch. globosum NRRL 1870 - - - - - - - 
Cl. cladosporioides NIOSH 17-28-17 - - - + - - - 
Cl. sphaerospermum ATCC 11288 - - - - - - - 
Ex. rostratum ATCC 26856 - - - - - + + 
Fu. moniliforme NIOSH 32-40-16 - - - - - - - 
Fu. oxysporum NIOSH 32-40-14 - - - - - - - 
Ne. fischeri NIOSH 29-53-20 - - - - - - - 
Pa. variotii ATCC 66705 - - - - - + + 
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Pe. chrysogenum NRRL 1951 - - - - - - - 
Pe. expansum NRRL 973 - - - - - - - 
Pe. melinii NIOSH 32-46-01 - - - - - - - 
Pe. purpurogenum NRRL 1062 - - - - - - - 
Sc. brumptii ATCC 16278 - - - - - - - 
Tr. harzianum NIOSH 29-32-13 - - - - - + + 
Tr. viride ATCC 16640 - - - - - - - 
 
Table 5.1- Cross-reactivity profiles of terrelysin-mAbs analyzed by Western blot. As: Aspergillus, Ac: 
Acremonium, Al: Alternaria, Ch: Chaetomium, Cl: Cladosporium, Ex: Exserohilum, Fu: Fusarium, Ne: 
Nesosartorya, Pa: Paecilomyces, Pe: Penicillium, Sc: Scopulariopsis, Tr: Trichoderma. ✚: Positive reactivity. 
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5.3.4 Epitopes for rTerrelysin-mAbs- Owing to the high specificity determined in cross-
reactivity studies, 3 mAbs (15B5, 13G10 and 10G4) were tested to determine their epitopes 
using overlapping decapeptides that span the entire sequence of rTerrelysin. For mAb 15B5, 2 
spots were recognized at positions 20-21 (Fig. 5.4). The sequence of spots 20 and 21 correspond 
to ‘SFLYEGQFHS’ and ‘LYEGQFHSPE’ respectively. These data suggest that the epitope 
recognized by mAb 15B5 is ‘LYEGQFHS’. 
 After ensuring complete removal of bound mAb 15B5 and regeneration of the SPOTs 
membrane, the membrane was then scanned using mAb 13G10. Four consecutive spots (52-55) 
reacted with mAb 13G10 and the resultant epitope was ‘PSNEFE’. Subsequently, mAb 10G4 
was found to recognize the same epitope as mAb 13G10 based on SPOTscan data. SPOTscan of 
membrane using control mAb 9B4 and secondary antibodies did not result in reactivity to any 





Fig. 5.4 Epitope mapping of anti-rTerrelysin mAbs. SPOTs membrane scans for mAbs 15B5, 13G10 and 10G4. 
Each spot represents a decapeptide of rTerrelysin sequence. Decapeptides were sequential with an overlap of 2 
amino acids and spanned the entire sequence of rTerrelysin including the N-terminal purification Strep-tag II 
and the Factor Xa cleavage site. mAb 15B5 recognizes the epitope ‘LYEGQFHS’, while mAbs 13G10 and 10G4 




5.3.5 Time-point kinetics of expression of terrelysin- The expression of native terrelysin was 
examined using an inhibition ELISA to quantify the amount of terrelysin in CSN and ME at 24 
hr intervals (Fig. 5.5a). In ME, the highest relative concentrations of terrelysin were observed 
during the first few days of growth ranging between 10-12 µg/mg of total fungal protein. A 10-
fold reduction was observed by day 4-5 (1 µg/mg of total protein) and after day 6, very little 
terrelysin was quantified in ME. Lower levels of terrelysin were detected in the CSN with a 
maximum at day 6 and then declining to nearly baseline by day 12. 
 The morphological features that were observed at the same time intervals are depicted in 
Fig. 5.5b. The early time points when expression of terrelysin was the highest, involved the 
initial stages of conidial germination and hyphal extension (12 hrs to 24 hrs). Hyphal aggregation 
was observed up to 96-120 hrs, when quantities of terrelysin were observed to decline. Beyond 
this time interval, the morphological changes could not be differentiated. Collectively, these 
results suggest that terrelysin expression occurs during initial stages of fungal growth between 
days 0-4. When hyphal aggregation is complete, a concurrent reduction in the production of 
terrelysin was observed. Terrelysin was detected in the CSN at each measured time interval with 
peak concentrations observed on day 6. 
 As A. terreus is thermotolerant, this experiment was repeated at 37°C to further compare 
morphological stages with terrelysin production. Again, cultures were grown for 12 days and ME 
and CSN was collected at 24 h intervals. Overall the growth of A. terreus was accelerated and 
the morphological stages of conidial germination and hyphal extension occurred earlier 
compared to RT treatments (Fig. 5.6b). Terrelysin expression was highest on day 1 (12 µg/mg of 
total protein) and decreased 3-fold by day 2 (4 µg/mg of total protein) (Fig. 5.6a). The 
concentration of terrelysin was further reduced 8-fold by day (0.5 µg/mg of total protein). In 
 153
CSN, comparatively higher proportion of terrelysin was detected during initial growth at 37°C 
compared to RT; however, there was a decline in the concentration of terrelysin in the CSN at 
37°C. 
 In summary, we observed that terrelysin expression is concurrent with conidial 
germination, hyphal extension and aggregation. Terrelysin concentration declined on formation 











Fig. 5.5b. Morphological changes and progression of A. terreus culture growth at RT. Black arrows point to 
germinating conidia and hyphal extension in early cultures. Bar sizes correspond to 10 µm for 0-24 hrs and 100 
µm for 48-120 hrs. 
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Fig. 5.6b. Morphological changes and progression of A. terreus culture growth at 37°C. Black arrows point to 
germinating conidia and hyphal extension in early cultures. Bar sizes correspond to 10 µm for 12-24 hrs and 100 
µm for 36-72 hrs. 
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5.3.6 Immunolocalization of terrelysin- The cellular localization of terrelysin was examined 
by immunohistochemical staining methods using the terrelysin-specific mAb 15B5. Terrelysin 
was widely distributed within the hyphae (Fig. 5.7), with staining often of greater intensity near 
the hyphal tips. This pattern was distinctly different than the positive control (mAb 13E11) that 
stained a leucine aminopeptidase, a secreted protease within the extracellular matrix of the 






Fig. 5.7. Immunolocalization of terrelysin in A. terreus hyphae. Immunolocalization of the antigens was 
determined AlexaFluor® 594-labeled goat anti-mouse IgG secondary antibodies (Red) and nuclear staining was 
identified through DAPI staining (Blue). mAb 13E11 served as a positive control and stains specifically for A. 




Aspergillus terreus is an emerging opportunistic pathogen reported to be an etiological 
agent of fatal disseminated infections in immunocompromised populations (21-23). Due to the 
ability of this species to grow optimally at internal body temperature and produce accessory 
conidia, this filamentous fungus is capable of initiating an infection and disseminating within the 
body. Resistance to antibiotic treatment such as amphotericin B allows for a longer infection 
time until effective treatment. A combination of these factors facilitates rapid dissemination of 
the fungus and can result in mortality. To date, very little is known about the overall 
pathogenesis and involvement of specific virulence factors of A. terreus during infection.  
In A. fumigatus infections, asp-hemolysin was reported in tissues of experimental animals 
in an infection model and a role for hemolysin as potential virulence factors had been previously 
suggested (4, 7, 24, 25).  
Previously, the gene for terrelysin was cloned and used to produce a recombinant protein 
as described in chapter 4. In this study, rTerrelysin was used as the antigen for the development 
of terrelysin-specific mAbs, which were then utilized to characterize terrelysin expression during 
A. terreus growth. Four of the 11 mAbs (3B2, 6D2, 16C7 and 2D3) did not react to native 
terrelysin in A. terreus ME. Two possibilities for this include; a) the mAbs recognized the N-
terminal tag associated with rTerrelysin or b) their epitopes may be modified by post-
translational processes under natural conditions as there is putative N-glycosylation (N-X-S/T) 
sites in the terrelysin sequence. One antibody (mAb 2D3) reacted with purified recombinant 
proteins (rEnolase from Chaetomium globosum and rHev b 5 an allergen from Hevea 
brasiliensis) expressed in the same pASK-IBA6 vector (data not shown). It was concluded that 
mAb 2D3 recognizes an epitope in the N-terminal tag expressed by this vector. Epitope mapping 
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showed that mAb 2D3 recognizes the Strep-tag II sequence ‘WSHPQFEK’ (data not shown). 
The other 3 mAbs did not show reactivity to the other recombinant proteins, thus it is possible 
that their epitopes are conformational or blocked by post-translationally modifications to the 
native protein.  
In order to be useful as a diagnostic tool for the serological detection of terrelysin, it is 
essential that the mAb be species-specific. We tested 5 A. terreus strains, including the strain 
used for genome sequencing (NIH 2624/FGSC A1156). All mAbs tested detected terrelysin 
expressed in this strain. Interestingly, 7D8 showed reactivity towards 3/5 strains of A. terreus 
tested and while low affinity might explain this inconsistent detection, genetic diversity within 
the epitope for this mAb is also a possibility. Although additional strains from different clinical 
and environmental isolates were not tested, the data suggests consistent expression of terrelysin 
across strains. Recently, a new species, A. alabamensis, which is phenotypically homologous but 
genetically different to A. terreus was isolated from immunocompetent patient populations (26). 
It will be important to test the reactivity of these mAbs to A. alabamensis as well as other fungal 
species within Section Terrei such as A. carneus and A. niveus, which can also cause infections 
under rare circumstances (27, 28). 
The terrelysin mAbs did not cross-react to ME from other clinically relevant Aspergillus 
species such as A. fumigatus, A. flavus and A. niger. Weak reactivity was observed for mAb 
15C5 with A. nidulans and A. parasiticus in Western blots. This reactivity was restricted to high 
molecular weight proteins of ~ 50 and ~ 60 kDa and probably represents non-specific staining. 
Using cross-reactivity data, we identified 3 mAbs (13G10, 15B5 and 10G4) that did not cross-
react with any of the tested species. These 3 highly specific mAbs are important candidates for 
immunodiagnostic detection of A. terreus in clinical samples. Based on epitope mapping studies, 
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we identified 2 different epitopes recognized by these antibodies. mAb 15B5 (IgG1) recognized 
the epitope ‘LYEGQFHS’ while both mAbs 13G10 (IgG1) and 10G4 (IgG2a) recognized the 
epitope ‘PSNEFE’. These epitope sequences were not identified in homologous hemolysins 
derived from other fungal species with known aegerolysin sequences (Fig. 4.1).  
Expression of hemolysin in relation to growth has been studied previously for Pleurotus 
ostreatus and Pseudomonas aeruginosa (12, 13, 29). For P. ostreatus, a basidiomycete, the 
greatest expression of ostreolysin was observed during the initial stages of fungal fruiting. For 
the bacteria P. aeruginosa, it was observed that the expression of its hemolysin, PA0122 is 
highest in the stationary phase of growth (29). In contrast, limited information is available for the 
expression of aegerolysins in ascomycetes. Recent studies have reported high asp-hemolysin 
transcript levels in developing hyphae of A. fumigatus (30). In the present study, the expression 
of terrelysin was associated with morphological stages of A. terreus growth. The presence of 
terrelysin was highest during initial growth stages that encompassed conidial germination, 
hyphal extension and hyphal aggregation (‘log phase’). During stationary growth phases, (lack of 
increase in mycelial pellet size) detection of terrelysin was significantly reduced. This was 
observed at earlier time points when cultures were grown at 37°C and the presence of terrelysin 
consistently correlated with the morphological changes. These findings are consistent with 
studies by Swedish mycologist Lars Rutqvist which showed that the hemolytic principle could be 
purified from A. fumigatus mycelia only during a limited period of incubation at room 
temperature and that this period was earlier and shorter at 37°C (31).  
Using an inhibition ELISA, terrelysin was detected in CSN even though we did not 
identify a signal peptide on the terrelysin sequence using SignalP 3.0 (32). This is in contrast to 
an earlier report where terrelysin was not identified in the secretome of A. terreus. Whether the 
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detection of terrelysin in CSN a result of active secretion, hyphal degradation, fragmentation or 
due to involvement of unique secretory processes is currently not known and is the focus of 
future research. Recently, asp-hemolysin was identified as one of the most abundant protein in 
the A. fumigatus secretome even though the protein does not possess a signal peptide as noted 
earlier (33). Other studies have highlighted secretion of proteins with no predicted signal 
sequence and have proposed non-conventional secretory mechanisms (34-36). At day 6 in RT 
cultures and day 4 at 37°C, small increases in levels of terrelysin were observed in CSN. Hyphal 
fragmentation was observed at these time points and this could, in part, explain the presence of 
terrelysin in CSN. Our immunolocalization studies demonstrate a uniform distribution of 
terrelysin within A. terreus hyphal cytoplasm with greater reactivity localized at the hyphal tips. 
The hyphal tips are a region of extensive metabolic activity and consist of higher concentrations 
of proteins compared to regions trailing the hyphal tip. Based on these morphological and 
immunohistochemical observations, it appears that terrelysin is expressed during early stages of 
growth, probably during the emergence of hyphae from conidia and active hyphal growth.  
In summary, 7 terrelysin mAbs were characterized and 3 were identified to be highly 
specific for A. terreus. These mAbs were used to show that terrelysin is expressed during 
conidial germination and early growth of A. terreus hyphae. Since terrelysin was detected in 
CSN, it is possible that it could be detected in the serum of infected patients; however, this 
aspect has not been confirmed and remains the focus of future research. Serologic detection of 
terrelysin would make terrelysin useful as a biomarker, however the early expression of 
terrelysin in A. terreus growth may limit its usefulness for detecting infection. The kinetics of 
terrelysin production in vivo is unknown and more studies are required. 
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6.1 INTRODUCTION  
Recent interest in fungal hemolysins was stimulated by an association of Stachybotrys 
chartarum with an outbreak of idiopathic pulmonary hemorrhage (IPH) in Cleveland (1). 
Stachybotrys chartarum in particular was isolated from the homes of infants with IPH.  Fungal 
proteins capable of hemolysis (hemolysins) were postulated as the causative agent and 
stachylysin was proposed as a potential biomarker for exposure to Stachybotrys chartarum (2-4). 
Detection of hemolysins in sera and tissues of experimentally exposed animals and in some 
humans working in chronic exposure environments further fueled an interest in utilizing fungal 
hemolysins as biomarkers for fungal exposure (4, 5). Thus methods of detecting and quantifying 
stachylysin were necessary to better understand this association.  
 Stachylysin was first proposed as a potential biomarker for detection of exposure to 
Stachybotrys chartarum based on immunoassays using a poorly characterized polyclonal 
antiserum (4). In order to verify stachylysin as a biomarker, we developed mAbs to stachylysin 
preparation in collaboration with Dr. Steve Vesper at the Environment Protection Agency in 
Cincinnati, OH. The initial goal of this project was to develop S. chartarum-specific mAbs and 
the development of rapid detection assays for stachylysin from environmental and clinical 
samples. However, the hemolytic antigen preparation contained multiple proteins making a 
monoclonal antibody to stachylysin difficult to obtain.  Since, the genome of S. chartarum has 
not been sequenced, we then shifted the focus to studying similar Aegerolysins from a well 
characterized fungal species where the genome has been sequenced. We chose to study the 
hemolysin from A. terreus, an emerging pathogen, especially for immunocompromised patients 
(6, 7). As the first step of this strategy, we developed mAbs to a similar hemolytic preparation 
purified from A. terreus culture medium. We successfully obtained IgG1 mAbs that were highly 
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specific for A. terreus, however, on initial characterization of the mAbs; we again identified 
reactivity to multiple proteins with little evidence of reactivity to a hemolysin. On further 
characterization, we elucidated that the mAbs recognized proteolytic enzymes secreted by A. 
terreus. 
Since, the genome of A. terreus had been sequenced, our next approach involved 
identifying terrelysin, using homology to the sequence information available for asp-hemolysin, 
the Aegerolysin of A. fumigatus. We subsequently produced a recombinant terrelysin using the 
pASK-IBA6 vector in an E. coli host. The recombinant protein then served as the antigen and 
murine mAbs of IgG1, IgG2a and IgG2b isotypes were generated against rTerrelysin. These mAbs 
are highly specific to A. terreus and have the potential for developing diagnostic assays for 
detection of A. terreus in environmental and clinical samples.  
 
6.2 STACHYLYSIN  
As noted above, a goal of this project was to develop mAbs to stachylysin, a molecule 
that had been previously characterized in multiple studies using a polyclonal antiserum (2-4, 8). 
The data published using this polyclonal reported there were very high levels of stachylysin in 
the lungs and sera of exposed animals (10.9 ng/ml and human (371 ng/ml) suggesting the assay 
was subject to interferences or inaccuracy. It was reasoned that a mAb would produce a more 
accurate and reproducible assay and also improve the specificity of the assay. Using the 
hemolytic preparation developed by Dr. Vesper’s group. (2), we developed murine mAbs to this 
partially purified hemolytic fraction. Although the extract was purified from S. chartarum, the 
specific strain was later identified and characterized as a related species called S. chlorohalonata 
(9). The obtained mAbs showed consistent reactivity to hyphal extracts from multiple strains of 
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both S. chartarum and S. chlorohalonata and the reactivity were notably weaker to conidial 
extracts. This also confirmed an earlier report that stachylysin was expressed in higher 
concentrations in the hyphae (4). We also observed significant reactivity of the mAbs to hyphae 
in immunohistochemical localization studies using the halogen immunoassay. Interestingly, most 
reactivity to hyphal structures was concentrated at septal junctions and hyphal branch points. 
Repeated attempts to confirm that stachylysin was the antigen recognized by the mAbs were not 
successful undoubtedly due to the fact that these hemolytic preparations used as an antigen 
source, do not appear to contain the Aegerolysins.  
One of the goals was to develop IgG mAbs for better utility in immunoassays; however, 
we only identified IgM mAbs to the S. chlorohalonata hemolytic preparation. The screening 
procedure used antibodies to IgG and IgM isotypes to ensure identification of the greatest 
number of clones. This enabled us to detect IgM mAbs, but the nature of the immune response 
appears to have been primarily IgM after 6 immunizations with the hemolytic preparation. This 
is likely due to the presence of glycoproteins in the hemolytic preparation. Previously in our lab, 
we have reported difficulty in generation of detectable IgG titers in animals immunized with 
conidial, hyphal or secreted antigens, with similar issues (10).  
The mAbs were developed to the hemolytic preparation with the primary purpose of 
identifying S. chartarum stachylysin. While we could not confirm the presence of stachylysin, 
the mAbs are species specific and react to hyphal extracts from both atranone as well as 
satratoxin producing chemotypes of S. chartarum. Although some cross-reactivity was observed 
with other closely related fungal species such as Memnoniella species, overall the IgM mAbs 
showed good specificity to Stachybotrys species. Reactivity to conidia was minimal but 
detectable using assays developed here. Since no mAbs are available for detection of 
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Stachybotrys hyphal antigens and these antigens are expressed in high concentrations in hyphae, 




The genome of Stachybotrys species has not been sequenced which hampered our efforts 
to identify stachylysin and hence we focused on characterization of a hemolysin in a fungus 
whose genome had been sequenced. The genome of A. terreus was recently sequenced (11) and 
we identified the sequence for the hemolysin based on the homology to asp-hemolysin of A. 
fumigatus. In our first approach, Dr. Vesper’s group at EPA, Cincinnati, OH, purified terrelysin 
using the previously used biochemical methods (2, 12). With the knowledge that this preparation 
was only partially purified, the preparation was identified as a cytolytic A. terreus preparation 
(cAtp) in our studies.  
Using this preparation, we successfully developed highly specific IgG1 mAbs to cAtp in 
mice. Initial analysis of the anti-cAtp mAbs using Western blot analysis showed multiple bands 
suggesting that the mAbs might react to different proteins that co-purified with the hemolysin. 
No mAbs exhibited reactivity to an 18 kDa protein, the expected molecular weight of terrelysin. 
However, we did observe reactivity to multiple high molecular weight bands, suggesting that the 
epitopes might be shared between different proteins or the high molecular weight proteins might 
be aggregates of terrelysin.  
Using immunoprecipitation and subsequent proteomic analysis of the immunoreactive 
bands, we identified leucine aminopeptidase (LAP) and dipeptidyl peptidase V (DPP 5) as two 
antigens of cAtp. We did not identify any peptides with the terrelysin sequence in the cAtp 
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preparation. As previously noted for stachylysin, higher concentrations of LAP and DPP 5 were 
detected in the hyphae than the conidia. Also, we detected high levels of these proteins in A. 
terreus CSN, suggesting that these proteins might be secreted. Indeed, we identified putative 
signal peptides in the N-terminal domain of the sequences of these proteins. Also, on 
investigation of the kinetics of expression of these proteins, we observed a lag period between 
expression of the antigens within the hyphae and in the growth medium, suggesting involvement 
of active secretion processes. 
 In immunolocalization studies, we observed that LAP staining was predominantly outside 
the growing hyphae in extracellular structures. These extracellular structures also stained with 
DAPI for DNA, and genetic material has been reported as part of the extracellular matrix of the 
fungi (13, 14). Presumably, fungi use these structures to anchor to the substrate on which they 
colonize. Little is known about the clinical significance of fungal ECM and LAP. Interestingly, 
these proteins were detected in the fungal growth medium throughout the course of the 
expression studies. In previously reported studies, DPP 5 has been reported as an important 
serodiagnostic marker for A. fumigatus (15, 16) and recently identified as the 3
rd
 most abundant 
protein among the secreted proteins of A. fumigatus (17). These results highlight the potential of 
mAbs developed in this study for serodiagnostic assays for detection of A. terreus.  
 
6.4 RECOMBINANT TERRELYSIN  
Our goal of identifying terrelysin using previously described biochemical methods was 
not achieved and required a different strategy. We utilized the A. terreus genome sequence 
information available in the database to identify a homologue to asp-hemolysin of A. fumigatus 
and used molecular techniques for cloning and expression of terrelysin. In our first attempt to 
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produce recombinant terrelysin, we expressed the clone in E. coli, and purified the protein using 
the His6-tag at the N-terminus of the expressed protein. We did not observe any hemolytic 
activity with this construct and also encountered problems of impurities after purification on Ni-
column. One of the reasons for the lack of hemolytic activity could be that the protein expressed 
using this system was localized within E. coli cytoplasm where reducing conditions may not 
permit proper folding of the protein. Folding of the hemolytic proteins and the associated 
conformational changes play a vital role in the mechanism of hemolysis (18). 
To address this issue, we expressed the protein in the pASK-IBA6 vector, which utilizes 
a signal peptide at the N-terminus of the vector sequence that enables efficient expression of the 
protein in the periplasmic space. Here, the conditions are more favorable for the proper folding 
of the expressed recombinant protein. Also, the high affinity Strep-tag II allows for purification 
of the expressed recombinant protein under physiological conditions. Using recombinant protein 
produced in this system, we confirmed the secondary structure of terrelysin using CD techniques 
and also assessed the conformational changes resulting from changes in pH and temperature. The 
observations were similar to those previously reported for native ostreolysin, an Aegerolysin 
purified from the mushroom P. ostreatus (19). 
Murine mAbs were raised to the rTerrelysin and characterized for reactivity to native 
terrelysin and also for cross-reactivity towards other fungal species. Except for one, all of the 
mAbs to recombinant terrelysin also recognized the native terrelysin in extracts from different 
strains of A. terreus including the pathogenic FGSC A1156 strain. Three of the mAbs reacted to 
hyphal extracts from other fungal species, while 3 mAbs did not show any cross-reactivity. 
These 3 A. terreus-specific mAbs, 13G10, 15B5, and 10G4 were used for further 
characterization of terrelysin. Epitope mapping results showed that mAb 15B5 recognizes a 
 174
different epitope than mAbs 13G10 and 10G4. The epitopes recognized by these mAbs were also 
absent in fungal species in which homologous Aegerolysin family hemolysins have been 
identified. Overall, these mAbs have the potential for use in developing double monoclonal 
antibody-based diagnostic assays for highly specific and sensitive assays for the early detection 
of terrelysin in clinical and environmental samples. 
We also studied the kinetics of terrelysin expression and correlated it with the 
morphological changes during growth of A. terreus. We observed that terrelysin expression was 
high during the initial 3 days of growth but its concentration diminished with the increasing 
fungal biomass, and was essentially non-detectable in mycelium from the 7-day old cultures that 
were used by Dr. Vesper to make isolate the hemolytic antigen preparations. Also, we detected 
some terrelysin in the A. terreus growth CSN. Although terrelysin does not possess a putative 
signal peptide; it has been reported that fungi possess non-classical strategies for protein 
secretion (20-22). Interestingly, terrelysin was not identified in the A. terreus secretome (23), 
however, a recent study identified that although asp-hemolysin does not have a signal peptide, it 
was the 4
th
 most abundant protein in the A. fumigatus secretome (17). These discrepancies 
suggest that although hemolysins may be secreted proteins they are differentially expressed and 
regulated in filamentous fungal species. 
Our studies demonstrate the difficulties of using a biochemical approach for isolation and 
characterization of hemolytic proteins from fungi. Previously asp-hemolysin and ostreolysin 
were purified from A. fumigatus and P. ostreatus respectively, using similar biochemical 
methods (hemolytic fractions of separated proteins) (12, 24). This resulted in the purification of 
homologous Aegerolysins with similar biochemical and pathogenic properties. However, using 
similar methods for the purification of stachylysin and terrelysin did not result in purification of 
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Aegerolysin proteins. For A. terreus at least, we were able to determine that our mAbs detected 
the proteases, LAP and DPP 5. It is now apparent that the hemolytic activity that was followed 
during the purification of the “hemolysin” was likely contributed by these proteases. Proteases 
have been previously shown to have hemolytic activity (25, 26). To further corroborate this 
point, in a recently published report on asp-hemolysin, hemolysis and cytotoxicity was not 
altered using deletion mutants for asp-hemolysin (17). This work together with ours, 
demonstrates that Aegerolysin family proteins are not the major hemolytic factors in fungal 
extracts.  
 
6.5 OTHER CONCLUSIONS  
In our studies with Stachybotrys, Western blot staining with our mAbs identified a 30 
kDa protein as a putative Aegerolysin using a monoclonal antibody developed after 
immunization with the hemolytic protein preparation. Previously, stachylysin was reported as a 
12 kDa protein that migrates in SDS-PAGE as a 30 kDa protein (2). It was suggested that 
stachylysin may be a highly acidic protein and such proteins have been previously reported to 
demonstrate anomalous behavior in SDS-PAGE (27). However, based on our findings with A. 
terreus, we should reinterpret that data as it likely represents a protease from Stachybotrys. 
In this study for the first time we have cloned and expressed terrelysin and to date it is the 
only Aegerolysins from A. terreus that has been identified and cloned. Although we did observe 
hemolytic activity with the purified recombinant protein, because of the possibility of 
contamination of the purified rTerrelysin preparation with surfactants, we could not be sure the 
hemolytic activity was due to rTerrelysin. Although we did not examine the role of terrelysin in 
pathogenesis, recent studies using asp-hemolysin mutants show that asp-hemolysin may not be 
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important for virulence and may be dispensable for pathogenesis (17). This challenges earlier 
observations regarding the role of asp-hemolysin in pathogenesis of A. fumigatus (5, 12, 28-30). 
The concentration of asp-hemolysin used in these studies may not necessarily be at levels 
achieved during an in vivo infection. 
Reagents developed in these studies will be beneficial in developing standardized and 
rapid diagnostic tests for diagnosis of environmental and clinical exposure to Stachybotrys 
species and A. terreus. For A. terreus, mAbs developed to hyphal exoantigens such as LAP and 
DPP 5 used in combination with mAbs developed to terrelysin may be helpful in developing 
surveillance assays for A. terreus. Since terrelysin is expressed early during growth, its detection 
may suggest early infection, while detection of LAP and DPP 5 and reduced levels of terrelysin 
may suggest late infection. On treatment, levels of LAP and DPP 5 may be monitored to assess 
efficacy of treatment and clearance of A. terreus infection. 
However, we have limited information regarding the expression and the stability of these 
proteins in vivo during infection. Studies utilizing animal models for invasive aspergillosis in 
immunocompromised mice will help in determining the presence of these proteins in various 
clinical samples. Some studies have reported presence of these proteins in urine samples 
collected from patients (31). Development of dip-stick based assay kits may also introduce 
portability. 
Collectively these mAbs have tremendous potential in development of diagnostic assays 
for Stachybotrys species and A. terreus exposures. The improved methodologies described in 
these studies will help in better and consistent characterization of fungal growth and protein 
expression. Tools and methodologies developed in these studies will also be useful in developing 
highly specific double monoclonal antibody based assays.  
 177
6.6 REFERENCES 
1. CDC. 1994. Acute pulmonary hemorrhaging/hemosiderosis among infants: Cleveland, 
January 1993-November 1994. In Morbid Mortal Weekly Rep. Centers for Disease 
Control and Prevention. 881-883. 
2. Vesper, S. J., M. L. Magnuson, D. G. Dearborn, I. Yike, and R. A. Haugland. 2001. 
Initial characterization of the hemolysin stachylysin from Stachybotrys chartarum. Infect 
Immun 69:912-916. 
3. Vesper, S. J., and M. J. Vesper. 2002. Stachylysin may be a cause of hemorrhaging in 
humans exposed to Stachybotrys chartarum. Infect Immun 70:2065-2069. 
4. Van Emon, J. M., A. W. Reed, I. Yike, and S. J. Vesper. 2003. ELISA measurement of 
stachylysin in serum to quantify human exposures to the indoor mold Stachybotrys 
chartarum. J Occup Environ Med 45:582-591. 
5. Ebina, K., K. Yokota, and O. Sakaguchi. 1982. Studies on toxin of Aspergillus fumigatus 
XIV: Relationship between Asp-hemolysin and experimental infection in mice. Jpn J 
Med Mycol 23:246-252. 
6. Iwen, P. C., M. E. Rupp, A. N. Langnas, E. C. Reed, and S. H. Hinrichs. 1998. Invasive 
pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the 
literature. Clin Infect Dis 26:1092-1097. 
7. Hachem, R. Y., D. P. Kontoyiannis, M. R. Boktour, C. Afif, C. Cooksley, G. P. Bodey, I. 
Chatzinikolaou, C. Perego, H. M. Kantarjian, and Raad, II. 2004. Aspergillus terreus: an 
emerging amphotericin B-resistant opportunistic mold in patients with hematologic 
malignancies. Cancer 101:1594-1600. 
8. Vesper, S. J., and M. J. Vesper. 2004. Possible role of fungal hemolysins in sick building 
syndrome. Adv Appl Microbiol 55:191-213. 
9. Andersen, B., K. F. Nielsen, U. Thrane, T. Szaro, J. W. Taylor, and B. B. Jarvis. 2003. 
Molecular and phenotypic descriptions of Stachybotrys chlorohalonata sp. nov. and two 
chemotypes of Stachybotrys chartarum found in water-damaged buildings. Mycologia 
95:1227-1238. 
10. Schmechel, D., J. P. Simpson, and D. M. Lewis. 2005. The production and 
characterization of monoclonal antibodies to the fungus Aspergillus versicolor. Indoor 
Air 15 Suppl 9:11-19. 
11. Birren, B. W., E. S. Lander, J. E. Galagan, C. Nusbaum, K. Devon, M. Henn, L. J. Ma, D. 
B. Jaffe, J. Butler, P. Alvarez, S. Gnerre, M. Grabherr, M. Kleber, E. W. Mauceli, W. 
Brockman, S. Rounsley, S. K. Young, K. LaButti, and K. Madden. 2005. Annotation of 
the Aspergillus terreus NIH264 genome. EMBL/GenBank/DDBJ databases. 
12. Sakaguchi, O., H. Shimada, and K. Yokota. 1975. Proceedings: Purification and 
characteristics of hemolytic toxin from Aspergillus fumigatus. Jpn J Med Sci Biol 28:328-
331. 
13. Loussert, C., C. Schmitt, M. C. Prevost, V. Balloy, E. Fadel, B. Philippe, C. Kauffman-
Lacroix, J. P. Latge, and A. Beauvais. 2010. In vivo biofilm composition of Aspergillus 
fumigatus. Cell Microbiol 12:405-410. 
14. Mowat, E., C. Williams, B. Jones, S. McChlery, and G. Ramage. 2009. The 
characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm? Med 
Mycol 47:S120-126. 
 178
15. Beauvais, A., M. Monod, J. P. Debeaupuis, M. Diaquin, H. Kobayashi, and J. P. Latge. 
1997. Biochemical and antigenic characterization of a new dipeptidyl-peptidase isolated 
from Aspergillus fumigatus. J Biol Chem 272:6238-6244. 
16. Biguet, J., P. Tran van Ky, and S. Andrieu. 1967. Identification d'une activité 
chymotrypsique au niveau de fractions remarquables d'Aspergillus fumigatus. 
Répercussions sur le diagnostic immunologique de l'aspergillose. Rev Immunol Ther 
Antimicrob 31:317-328. 
17. Wartenberg, D., K. Lapp, I. D. Jacobsen, H. M. Dahse, O. Kniemeyer, T. Heinekamp, 
and A. A. Brakhage. 2011. Secretome analysis of Aspergillus fumigatus reveals Asp-
hemolysin as a major secreted protein. Int J Med Microbiol. 
18. Gonzalez, M. R., M. Bischofberger, L. Pernot, F. G. van der Goot, and B. Freche. 2008. 
Bacterial pore-forming toxins: the (w)hole story? Cell Mol Life Sci 65:493-507. 
19. Berne, S., K. Sepcic, G. Anderluh, T. Turk, P. Macek, and N. Poklar Ulrih. 2005. Effect 
of pH on the pore forming activity and conformational stability of ostreolysin, a lipid 
raft-binding protein from the edible mushroom Pleurotus ostreatus. Biochemistry 
44:11137-11147. 
20. Rubartelli, A., and R. Sitia. 1997. Secretion of mammalian proteins that lack a signal 
sequence. In Unusual secretory pathways: From bacteria to man. K. Kuchler, A. 
Rubartelli, and B. I. Holland, eds. RG Landes, Austin, TX. 87-104. 
21. Nickel, W. 2010. Pathways of unconventional protein secretion. Curr Opin Biotechnol 
21:621-626. 
22. Lu, X., J. Sun, M. Nimtz, J. Wissing, A. P. Zeng, and U. Rinas. 2010. The intra- and 
extracellular proteome of Aspergillus niger growing on defined medium with xylose or 
maltose as carbon substrate. Microb Cell Fact 9:1-13. 
23. Han, M. J., N. J. Kim, S. Y. Lee, and H. N. Chang. 2010. Extracellular proteome of 
Aspergillus terreus grown on different carbon sources. Curr Genet 56:369-382. 
24. Berne, S., I. Krizaj, F. Pohleven, T. Turk, P. Macek, and K. Sepcic. 2002. Pleurotus and 
Agrocybe hemolysins, new proteins hypothetically involved in fungal fruiting. Biochim 
Biophys Acta 1570:153-159. 
25. Keen, M. G., and P. S. Hoffman. 1989. Characterization of a Legionella pneumophila 
extracellular protease exhibiting hemolytic and cytotoxic activities. Infect Immun 57:732-
738. 
26. Lee, C. Y., M. F. Cheng, M. S. Yu, and M. J. Pan. 2002. Purification and characterization 
of a putative virulence factor, serine protease, from Vibrio parahemolyticus. FEMS 
Microbiol Lett 209:31-37. 
27. Garcia-Ortega, L., V. De los Rios, A. Martinez-Ruiz, M. Onaderra, J. Lacadena, A. 
Martinez del Pozo, and J. G. Gavilanes. 2005. Anomalous electrophoretic behavior of a 
very acidic protein: ribonuclease U2. Electrophoresis 26:3407-3413. 
28. Sakaguchi, O., K. Yokota, and A. Kamaguchi. 1977. [Studies on the toxin of Aspergillus 
fumigatus. VIII. Biological properties of Asp-hemolysin (author's transl)]. Nippon 
Saikingaku Zasshi 32:821-828. 
29. Yokota, K., H. Shimada, A. Kamaguchi, and O. Sakaguchi. 1977. Studies on the toxin of 
Aspergillus fumigatus VII. Purification and some properities of hemolytic toxin (asp-
hemolysin) from culture filtrates and mycelia. Microbiol Immunol 21:11-22. 
 179
30. Ebina, K., K. Yokota, and O. Sakaguchi. 1983. Studies on toxin of Aspergillus fumigatus 
XVI. Biological properties of Asp-hemolysin as a parasite factor. Jpn J Med Mycol 
24:245-252. 
31. Latge, J. P., M. Moutaouakil, J. P. Debeaupuis, J. P. Bouchara, K. Haynes, and M. C. 
























A1. Amino acid composition similarity search. Search was performed using keyword ‘hemolysis’ and input of % 
amino acid composition of stachylysin. Swiss-Prot and TrEMBL constellation 0 was chosen for analysis. 
Protein Species Accession # 
Hydralysin-2 Burkholderia glumae HLYS2_CHLVR 
Hydralysin-1 Burkholderia glumae HLYS1_CHLVR 
Aerolysin Aeromonas sobria AERA_AERSO 
Aerolysin Aeromonas salmonicida AERA_AERSA 
Aerolysin Aeromonas trota AERA_AERTR 
Aerolysin-4 Aeromonas hydrophila AER4_AERHY 
Aerolysin-5 Aeromonas hydrophila AER5_AERHY 
Aerolysin-3 Aeromonas hydrophila AER3_AERHY 
Alveolysin Bacillus alvei TACY_PAEAL 
Hemolysin Vibrio cholerae HLYA_VIBCH 
Thermostable direct hemolysin 1 Vibrio parahemolyticus HLY1_VIBPA 
Echotoxin-2 Cymatium echo ACTP2_CYMEC 
Verrucotoxin subunit beta Synanceia verrucosa VTXB_SYNVE 
Pneumolysin Streptococcus pneumoniae TACY_STRPN 
Pneumolysin Streptococcus pneumoniae TACY_STRR6 
Pneumolysin Streptococcus pneumoniae TACY_STRP2 
Stonustoxin subunit alpha Synanceia horrida STXA_SYNHO 
Toxin A Carybdea alata CTXA_CARAL 
Thermostable direct hemolysin 2 Vibrio parahemolyticus HLY2_VIBPA 





A2. Sub divisions of Aspergillus species 
 
Sub genus Section (e.g. of representative species) 
1. Aspergillus a. Aspergillus- Aspergillus glaucus 
b. Restricti- Aspergillus penicilloides 
2. Fumigati a. Fumigati- Aspergillus fumigatus 
b. Clavati- Aspergillus clavatus 
3. Circumdati a. Circumdati- Aspergillus ochraceus 
b. Nigri- Aspergillus niger 
c. Flavi- Aspergillus flavus 
d. Cremei- Aspergillus wentii 
4. Terrei a. Terrei- Aspergillus terreus 
b. Flavipedes- Aspergillus flavipes 
5. Nidulantes a. Nidulantes- Aspergillus nidulans 
b. Usti- Aspergillus ustus 
c. Sparsi- Aspergillus sparsus 
d. Raperi- Aspergillus raperi 
e. Silvati- Aspergillus silvaticus 
f. Ochraceorosei- Aspergillus 
ochraceoroseus 
g. Bispori- Aspergillus bisporus 
6. Ornati a. Ornati- Sclerocleista ornata 
7. Warcupi a. Warcupi- Warcupiella spinulosa 
b. Zonati- Aspergillus zonatus 





A3. List of species in which Aegerolysins have been identified 
 
Aspergillus terreus Histoplasma capsulatum 
Aspergillus fumigatus Neurospora crassa 
Aspergillus oryzae Pleurotus ostreatus 
Aspergillus clavatus Agrocybe aegerita 
Aspergillus niger Spirosoma linguale 
Aspergillus flavus Pseudomonas aeruginosa 
Aspergillus nidulans Burkholderia glumae 
Penicillium chrysogenum Clostridium bifermentans 
Paracoccidioides brasiliensis Bacillus thuringiensis 





A4. Cytotoxicity of Aegerolysin proteins on different cell lines. Modified from (1) 
 
Protein Cell Line (Source) ED50 (µg/ml) References 
Asp-hemolysin Leukocytes (Human) 500 (2) 
 Alveolar macrophages 
(Guinea pig) 
60 (2) 
 Peritoneal macrophages 
(Mouse) 
25 (3) 
 Umbilical vein endothelial 
cells (Human) 
100 (4) 
Ostreolysin Fibrosarcoma HT 1080 
(Human) 
10 (5) 
 Mammalian tumor MCF 7 
(Human) 
10 (5) 
 Ovary cells (Chinese 
hamster) 
1 (6) 
 Articular chondrocytes 
(Human) 
1 (7) 
 Lung fibroblasts V-79-
379A (Chinese hamster) 
1.3 (8) 






A5. Protein A and G-based antibody immunoprecipitation 
Species Ig subclass Protein A Protein G 
Human IgG1, IgG2, IgG4 +++ +++ 
IgG3 + +++ 
IgD - - 
IgD + - 
Fab + + 
ScFv + - 
Mouse IgG1 + ++ 
IgG2a, IgG2b, IgG3 +++ +++ 
IgM - - 
Rat IgG1 + ++ 
IgG2a - +++ 
IgG2b - + 
IgG2c +++ +++ 
Goat/Sheep/Bovine IgG1 + +++ 
IgG2 +++ +++ 
Horse IgG(ab) + - 
IgG(c) + - 
IgG(T) - +++ 
Rabbit Total IgG +++ +++ 
Dog/Cat/Pig/Guinea 
Pig 
Total IgG +++ + 
Chicken Total IgG - - 
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